Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2014

Functional Characterization of a Novel Thioredoxin DomainContaining Protein of the Malaria Parasite Plasmodium
Rachel Kooistra
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Biology Commons

Recommended Citation
Kooistra, Rachel, "Functional Characterization of a Novel Thioredoxin Domain-Containing Protein of the
Malaria Parasite Plasmodium" (2014). Master's Theses. 2506.
https://ecommons.luc.edu/luc_theses/2506

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2014 Rachel Kooistra

LOYOLA UNIVERSITY CHICAGO

FUNCTIONAL CHARACTERIZATION OF A NOVEL THIOREDOXIN DOMAINCONTAINING PROTEIN OF THE MALARIA PARASITE PLASMODIUM

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN BIOLOGY

BY
RACHEL KOOISTRA
CHICAGO, ILLINOIS
AUGUST 2014

Copyright by Rachel Kooistra, 2014
All rights reserved

ACKNOWLEDGMENTS
First and foremost, I would like to thank my thesis advisor, Dr. Stefan Kanzok.
His door was always open for questions and concerns, and he always encouraged me to
come up with my own solutions and hypotheses. I am especially grateful for his
continuous support of my career goals, and for his willingness to listen to my complaints
when nothing seemed to be working out in lab. In addition, a huge thank you to every
member of the Kanzok lab (past and present), but especially to Robin David, Katie Fell,
Kyle Haselton, Sana Hira, Mike Lamm, and Shannon McGuire. Thank you also to my
committee members, Dr. Rodney Dale, Dr. Catherine Putonti, and Dr. Kim Williamson,
for their invaluable advice. Finally, thank you to other contributors to this project, Dr.
Kenneth Olsen, Dr. Andrew Blagborough, and Dr. Holly Goodson.

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS………………………………………………………………..iii
LIST OF FIGURES……………………………………………………………………...vii
LIST OF TABLES………………………………………………………………………..ix
CHAPTER I: INTRODUCTION…………………………………………………………1
Malaria and Plasmodium………………………………………………………………..1
Antioxidant Systems of Plasmodium…………………………………………………....3
Thioredoxin Superfamily of Proteins……………………………………………………5
Studying Plasmodium mosquito stages…………………………………………………7
Thesis Objective…………………………………………………………………………8
CHAPTER II: MATERIALS AND METHODS………………………………………...10
Reagents………………………………………………………………………………..10
Buffers, Media, and Solutions…………………………………………………………11
Accession Numbers……………………………………………………………………13
Parasite Maintenance and Mosquito Infections………………………………………..13
Cultivation of HepG2 and HeLa Cell Lines…………………………………………...13
Generation of Human and P. berghei cDNA…………………………………………..13
Isolation and Purification of P. berghei gDNA………………………………………..14
Polymerase Chain Reaction (PCR) of Target DNA…………………………………...15
TXNDC9……………………………………………………………………………..15
hTrx…………………………………………………………………………………..15
PbPhLP1 Knockout Construct……………………………………………………….16
Site-Directed Mutagenesis…………………………………………………………...17
TA Cloning of DNA Fragments into pGEM Vector…………………………………..17
Making DH5α and M15 Competent Using CaCl2……………………………………..18
E. coli Transformation (DH5α, JM109, M15, BL21)………………………………….18
Restriction Digests……………………………………………………………………..19
Ligation of Fragments into Vectors……………………………………………………19
Protein Expression……………………………………………………………………..19
Protein Purification…………………………………………………………………….19
Urea Purification……………………………………………………………………….20
SDS-PAGE…………………………………………………………………………….20
DNA Electrophoresis…………………………………………………………………..21
Construction of Transgenic P. berghei………………………………………………...21
Production of Schizonts and Purification……………………………………………21
Transfection of P. berghei with Amaxa Electroporation System……………………22
Drug Selection……………………………………………………………………….22
iv

Insulin Assays………………………………………………………………………….23
Immunoprecipitation of Protein from HeLa Cells……………………………………..23
Method 1……………………………………………………………………………..23
Modifications to Method 1…………………………………………………………...24
Method 2: Pierce Crosslink Immunoprecipitation Kit……………………………….25
Antibody cleanup…………………………………………………………………..25
Binding of antibody to Protein A/G Plus Agarose…………………………………25
Crosslinking bound antibody………………………………………………………26
Cell lysis…………………………………………………………………………...27
Pre-clear lysate using control agarose resin………………………………………..27
Immunoprecipitation……………………………………………………………….27
Sample preparation for SDS-PAGE analysis………………………………………28
Modifications to Method 2…………………………………………………………...28
Western Blots…………………………………………………………………………..28
Sample Preparation Using Parasite Lysate…………………………………………..28
Sample Preparation Using Recombinant Protein…………………………………….29
Sample Preparation Using Purified Tubulin…………………………………………29
Transfer from Gel to Nitrocellulose………………………………………………….30
Immunofluorescent Staining of Nitrocellulose Membrane…………………………..30
Immunofluorescence…………………………………………………………………...30
Paraformaldehyde/Glutaraldehyde Fixation…………………………………………30
Glutaraldehyde Fixation……………………………………………………………...31
Antibody Staining……………………………………………………………………31
Phalloidin Staining…………………………………………………………………...32
Imaging………………………………………………………………………………32
Thioredoxin System Assays……………………………………………………………32
Modeling……………………………………………………………………………….33
Phylogenetics…………………………………………………………………………..33
Sequence Comparison………………………………………………………………..33
Identifying Paralogs and Homologs………………………………………………….34
Deriving Phylogenetic Trees…………………………………………………………35
CHAPTER III: RESULTS……………………………………………………………….36
Preliminary Data……………………………………………………………………….36
Disruption of the pbtrx-469 Gene in P. berghei Parasites……………………………..41
Generation of the Knockout Construct………………………………………………43
pbtrx-469KO Parasites Are Not Viable……………………………………………...45
Biochemical Characterization of PbTrx-469…………………………………………..45
PbTrx-469 Reduces Insulin in the Insulin-Reduction Assay………………………...46
PbTrx-469 Exhibits Redox Activity with the Thioredoxin System………………….47
Modeling of PbTrx-469……………………………………………………………...50
Role of Cys106 in Redox Activity of PbTrx-469……………………………………51
Design of mutagenesis primers and cloning of PbTrx-469C106S…………………...51
Expression and purification of PbTrx-469C106S……………………………………52
v

PbTrx-469C106S shows significantly reduced redox activity in the insulin reduction
assay……………………………………………………………………………...53
PbTrx-469C106S is also inactive in the thioredoxin system…………………………54
Majority of PbTrx-469 Expressed in E. coli Is Insoluble…………………………....56
Characterization of Homologs of PbTrx-469………………………………………….58
IFA Studies Indicate that Anti-PbTrx-469 Antibodies Recognize a Protein Associated
with the Cytoskeleton in Human Cell Lines………………………………………58
Phylogenetic Analysis Reveals High Conservation of PbTrx-469 in Eukaryotes…...59
Immunoprecipitation to Determine the Target(s) of Anti-PbPhLP1 Antibodies in
Human Cells……………………………………………………………………….61
Anti-PbPhLP1 Antibodies Cross-React with Tubulin……………………………….66
Western Blots of Parasite Lysate…………………………………………………….70
Characterization of Human TXNDC9……………………………………………….71
Cloning, heterologous expression, and purification of recombinant hTXNDC9….72
Anti-PbPhLP1 antibodies cross-react with recombinant hTXNDC9……………...73
Conservation of PbPhLP1 active site………………………………………………75
Recombinant hTXNDC9 is active in the insulin-reduction assay…………………76
Thioredoxin reduction assay……………………………………………………….77
CHAPTER IV: DISCUSSION…………………………………………………………..80
REFERENCES…………………………………………………………………………..89
VITA……………………………………………………………………………………..96

vi

LIST OF FIGURES
Figure 1. Plasmodium life cycle…………………………………………………………..2
Figure 2. Thioredoxin redox system………………………………………………………4
Figure 3. The thioredoxin fold…………………………………………………………….5
Figure 4. P. berghei Trx-469…………………………………………………………….37
Figure 5. Expression of pbtrx-469……………………………………………………….38
Figure 6. Ni-NTA purification of PbTrx-469 from pQE9……………………………….38
Figure 7. Western blot with recombinant PbTrx-469 and PbTrx-1……………………...39
Figure 8. Expression and subcellular localization of PbTrx-469………………………...40
Figure 9. Anti-PbTrx-469 cross-reacts with a protein in HepG2 host cells……………...41
Figure 10. Disruption of trx-469 gene in P. berghei……………………………………..43
Figure 11. Generation of pbtrx-469 KO construct……………………………………….44
Figure 12. PbTrx-469 exhibits redox activity……………………………………………47
Figure 13. PbTrx-469 is active in the thioredoxin system……………………………….48
Figure 14. Kinetics for PbTrx-469 with PbTrx-1 as substrate…………………………...50
Figure 15. Model of PbTrx-469………………………………………………………….51
Figure 16. Site-directed mutagenesis of Cys106 in PbTrx-469………………………….52
Figure 17. Ni-NTA purification of PbTrx-469C106S from M15…………………………..53
Figure 18. Insulin assay using recombinant PbTrx-469 and PbTrx-469C106S……………54

vii

Figure 19. Activity of PbTrx-469 and PbTrx-469C106S in the thioredoxin reduction
assay…………………………………………………………………………………...55
Figure 20. Urea purification of PbTrx-469………………………………………………57
Figure 21. IFA of human cell lines using anti-PbTrx-469 antibodies…………………...58
Figure 22. Eukaryotic homologs of PbTrx-469………………………………………….60
Figure 23. Immunoprecipitation using anti-PbPhLP1 antibodies………………………..62
Figure 24. Western blot with immunoprecipitation pull down…………………………..65
Figure 25. Western blot of tubulin and PbPhLP1………………………………………..67
Figure 26. Western blot of tubulin and PbPhLP1 with Tubulin Beta Polyclonal
Antibodies……………………………………………………………………………..69
Figure 27. Western blot with parasite lysate and recombinant protein…………………..70
Figure 28. Size fractionation of PCR amplified hTXNDC9……………………………..72
Figure 29. Ni-NTA purification of hTXNDC9 from BL21……………………………...73
Figure 30. Western blot of tubulin, hTXNDC9, and PbPhLP1………………………….74
Figure 31. Conservation of putative active site………………………………………….76
Figure 32. Insulin assay testing recombinant hTXNDC9………………………………..77
Figure 33. hTXNDC9 is active in the thioredoxin system……………………………….78

viii

LIST OF TABLES
Table 1. Identity between P. berghei tubulins and PbPhLP1……………………………68
Table 2. Homologs of PbPhLP1…………………………………………………………80

ix

CHAPTER I
INTRODUCTION
Malaria and Plasmodium
In the 2013 World Malaria Report, the World Health Organization (WHO)
reported that 97 countries around the world had ongoing malaria transmission, accounting
for nearly 3.4 billion people at risk for contracting the disease. There were an estimated
207 million malaria cases in 2012, with approximately 627,000 deaths. 77% of these
deaths occurred in children under the age of five, meaning that malaria killed one child
almost every minute during that year. This loss of life took place in spite of $2.5 billion
of international and domestic funding, a number that the WHO suggests is less than half
of what is actually needed to control the disease (WHO, 2013).
This enormous toll on society is caused by an ancient, single-celled protozoan
parasite of the genus Plasmodium. To date, there are five species of Plasmodium known
to infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi (Oaks,
1991; Singh et al, 2004). Of these five, P. falciparum is considered to be the most deadly,
while P. vivax is the most widespread (Li et al, 2001). Malaria is a vector-borne disease,
and each of these species is transmitted to humans by female mosquitoes of the genus
Anopheles (Oaks, 1991).
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The life cycle of Plasmodium can be divided into three different stages: infection,
multiplication, and transmission. Infection begins when a mosquito feeds on a naïve host
and injects sporozoites into the host’s bloodstream. The sporozoites invade the liver cells,
where, over the next 5-15 days, they multiply asexually to produce schizonts, with each
schizont containing between 10,000 and 30,000 merozoites. Eventually the infected liver
cells rupture, and the merozoites are released into the bloodstream, where they proceed to
invade erythrocytes. Within the red blood cell, the merozoite starts an asexual
reproduction cycle in which it first matures into a trophozoite and then into a schizont to
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again produce more merozoites. When the red blood cell eventually bursts, these
merozoites will infect new red blood cells, and the multiplication process will start again
(Figure 1). The destruction of an increasing amount of red blood cells eventually leads to
the symptoms that characterize the disease malaria.
The transmission phase of the life cycle begins with the formation of male and
female gametocytes. When a mosquito takes a blood meal, it ingests gametocytes, which
mature into gametes and mate to form zygotes. The zygotes develop into motile
ookinetes, which move through the epithelial cells that line the midgut wall and develop
into sporozoite-forming oocysts. When the oocyst bursts, the released sporozoites invade
the mosquito’s salivary glands, from which they will be injected into another human host,
and the life cycle will begin again (Oaks, 1991) (Figure 1).
Antioxidant Systems of Plasmodium
Throughout its complex life cycle, the parasite is exposed to challenges and
stresses. For example, the majority of parasites ingested by the mosquito will perish
within the first 24 hours due to a number of factors, including mosquito-derived digesting
enzymes present in the mosquito midgut and the cytotoxic byproducts of their activity
(Alavi et al, 2003; Arambage et al, 2009). Damage may also be done to these parasites by
the immune components of the previous vertebrate host (Margos et al, 2001). In addition,
the mosquito mounts its own immune response against the parasite in the form of
antimicrobial peptides as well as reactive oxygen species (ROS) and reactive nitrogen
species (RNS), which can damage both DNA and cellular targets (Müller, 2004; Fang,
2004).
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In order to survive, Plasmodium must have the ability to create for itself a redox
environment that will minimize the damage caused by these stresses, while at the same
time allowing it to continue its own essential metabolic functions (Imlay, 2003). In order
to maintain this redox homeostasis, the parasite relies on two main antioxidant systems,
the glutathione system and the thioredoxin system (Figure 2), which are also conserved in
most eukaryotes (Müller, 2004).

The thioredoxin redox system consists of the oxidoreductase thioredoxin
reductase (TrxR) and the small protein thioredoxin (Trx), which supplies electrons to
various redox proteins, such as antioxidant thioredoxin-dependent peroxidases (Figure 2).
The thioredoxin system transports electrons via reduction-oxidation (redox) mechanisms,
a process that depends on thiol-containing cysteines present in the thioredoxin domain of
these proteins. In the first step of this system, the enzyme TrxR catalyzes the reduction of
oxidized thioredoxin [Trx-(S2)] (Holmgren, 1979; Kanzok, 2000). This leads to reduction
of the disulfide bond in Trx and subsequent formation of two thiol groups in reduced
thioredoxin [Trx-(SH)2]. These thiol groups can then reduce the disulfide bond in several
target proteins, including thioredoxin-dependent peroxidases (TPx) or other disulfide-
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containing substrate proteins (Holmgren, 1995). The expanding roles of this redox system
in Plasmodium are still a topic of study, and more evidence suggests that it may be
essential for the parasite. For example, the knockout of thioredoxin reductase has been
shown to be lethal to Plasmodium falciparum (Krnajski et al., 2002).
Thioredoxin Superfamily of Proteins
Thioredoxin and proteins that are reduced by the thioredoxin system are part of a
larger group of proteins known as the thioredoxin superfamily. This large family is
divided into two main groups, with Group I comprised of proteins that only contain a Trx
domain and Group II consisting of proteins that contain a thioredoxin domain along with
other domains (Sadek et al, 2003). The thioredoxin domain of these proteins folds into a
characteristic three-dimensional structure known as the thioredoxin (Trx) fold (Figure 3).
The basic structure of the Trx fold consists of an at least four-stranded beta sheet
surrounded by at least two alpha helices (βαβββα) (Martin, 1995; Atkinson and Babbitt,
2009).
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A subset of proteins in the thioredoxin superfamily have been shown to possess
redox activity (Atkinson and Babbitt, 2009). In general, redox activity of Trx-like
proteins is attributed to the presence of the amino acid cysteine in the active site of the
protein (Atkinson and Babbitt, 2009). The classical and widely conserved amino acid
sequence, or motif, that was first identified in thioredoxin and is commonly observed in
Trx-like proteins consists of two cysteine residues on either side of two other amino acids
(CXXC) (Holmgren, 1985). The sulfur-containing cysteine allows the proteins to exist in
either a reduced [Trx-(SH)2] or oxidized [Trx-(S2)] form (Holmgren, 1995). This enables
thioredoxins to reduce substrate proteins through the process of cysteine-thiol disulfide
exchange. Briefly, the thiolate of the peroxidatic cysteine of reduced thioredoxin [Trx(SH2)] allows for the nucleophilic attack of a disulfide group in a substrate protein,
leading to a mixed disulfide. A nucleophilic attack of the deprotonated resolving cysteine
then leads to the formation of an oxidized thioredoxin domain (Trx-[S2]) and reduced
substrate protein (Holmgren, 1995). However, more and more variations on this classical
active site have been found in thioredoxin fold containing proteins. Some proteins in the
thioredoxin superfamily possess only a single cysteine in their active site, while others
have no easily discernable active site (Atkinson and Babbitt, 2009).
The phosducin-like family of proteins was one of these groups of proteins in
which a catalytic motif was not readily detected (Atkinson and Babbitt, 2009). This
family of proteins is broadly conserved, with members appearing in all eukaryotic
organisms. Proteins belonging to this family contain a C-terminal thioredoxin domain,
but lack the classical CXXC active site (Marchler-Bauer et al, 2009). Phosducin-like
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proteins can be organized into three different subgroups (Willardson and Howlett, 2007).
Subgroup I consists of phosducin (Pdc) and phosducin-like protein 1 (PhLP1). Subgroup
II is represented in humans by two proteins, PhLP2A and PhLP2B, and in lower
organisms by a single protein, PhLP2. Subgroup III contains PhLP3, also known as
thioredoxin domain-containing protein 9 (TXNDC) or ATP binding protein associated
with cell differentiation (APACD). The work presented in this project sheds new light on
this subgroup of the thioredoxin superfamily of proteins.
Studying Plasmodium Mosquito Stages
As mentioned, Plasmodium is faced with particularly stressful conditions during
its first 24 hours in the mosquito midgut due to the presence of ROS and RNS (Luckhart
et al, 1998; Molina-Cruz et al, 2008). Once ingested by the mosquito, the parasite
gametes leave the host red blood cell, thus switching from an intracellular to an
extracellular lifestyle and exposing itself to the harsh environment of the mosquito
bloodmeal. The formation of a zygote takes place within an hour of ingestion.
Transformation from a zygote to an ookinete, however, forces the parasite to remain in
these severe conditions for up to 20 hours (Sinden et al, 2004). And while it is
hypothesized that members of the thioredoxin family of proteins play a role in defense
against this oxidative stress, very little is known about their protective mechanisms
(Nickel, 2006). A more thorough understanding of the specific functions of this protein
family in ookinetes may provide us with an indication of how to inhibit these proteins
and possibly prevent transmission of the parasite.
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The mouse malaria parasite Plasmodium berghei is an excellent model system for
studying the mosquito stages of Plasmodium for several reasons. Firstly, since P. berghei
is not infectious to humans, infected mosquitoes can safely be studied in a lab
environment. In addition, research with rodents does not carry the same ethical
implications as working with humans or other primates. Importantly, it has previously
been shown that all mammalian malaria parasites possess comparable life cycles as well
as similar morphological features of the different life stages (Sinden, 1978). The genome
organization between rodent-infecting parasites and human-infecting parasites is also
conserved (Janse et al, 1994; van Lin et al, 2001). In addition, mammalian malaria
parasites have not been found to possess any major differences in their metabolic
pathways (Janse and Waters, 1995). And while small differences in the way each species
interacts with its host do exist, P. berghei still provides us with a very useful starting
point from which to research many of the unknown aspects of this parasite.
Thesis Objective
While studies in Plasmodium have focused on the antioxidant functions of
thioredoxins, this group of proteins has been shown to play numerous other roles in other
organisms, including protein folding (Ito and Inaba, 2008), cell proliferation
(Immenschuh and Baumgart-Vogt, 2005), and signal transduction and transcriptional
regulation (Brigelius-Flohe and Flohe, 2011). Despite these findings, some studies
estimate that only 5.6% of proteins belonging to the thioredoxin superfamily have been
manually associated with a function (Atkinson and Babbitt, 2009). With this in mind, the
objective of this project was to characterize a novel thioredoxin domain-containing
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protein of the malaria parasite P. berghei. The results presented here not only serve to
begin to identify the function of this protein in Plasmodium, but may also provide new
insight into the functions of related proteins in other organisms.

CHAPTER II
MATERIALS AND METHODS
Reagents
All enzymes and enzyme buffers were obtained from Fermentas (Vilnius, Lithuania).
Unless otherwise stated, all primary antibodies were obtained from Open Biosystems
(Huntsville, AL). All PCR primers were obtained from Fisher Scientific (Fairlawn, NJ).
Agilent Technologies; Santa Clara, CA: BL21 CodonPlus Competent Cells, RNace-It
Ribonuclease Cocktail.
Amresco; Solon, OH: 2-mercaptoethanol (BME), glycerol, sodium dodecyl sulfate
(SDS), tris.
Bioexpress; Kaysville, UT: agar, fetal bovine serum (FBS), nuclease-free water, tryptone,
urea.
Cell Applications, Inc.; San Diego, CA: Bovine insulin.
Electron Microscopy Sciences; Hatfield, PA: Glutaraldehyde, 25% solution.
Enzo Life Sciences; Farmingdale, NY: NADPH tetrasodium salt.
Fisher Scientific; Fairlawn, NJ: ampicillin trihydrate, bovine serum albumin (BSA),
calcium chloride (CaCl2), chloramphenicol, chloroform, deoxycholic acid, dimethyl
sulfoxide (DMSO), glacial acetic acid, glycine, hydrochloric acid (HCl), imidazole,
isopropyl β-D-1-thiogalactopyranoside (IPTG), kanamycin sulfate, potassium phosphate
(KH2PO4), methanol, magnesium chloride (MgCl2), phenol, sodium borohydride, sodium
chloride (NaCl), sodium hydroxide (NaOH), sodium phosphate (Na2PO4), yeast extract.
Growcells.com; Irvine, CA: X-Gal powder.
Jackson ImmunoResearch Laboratories, Inc; West Grove, PA: Normal Donkey Serum.
Life Technologies; Carlsbad, CA: Alexa Fluor 488 Goat Anti-Rabbit IgG (H+L), Alexa
Fluor 555 Goat Anti-Mouse IgG (H+L), Alexa Fluor 555 Goat Anti-Rabbit IgG (H+L),
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beta-tubulin monoclonal antibody (mouse), DH5α competent E. coli, DNAse I, High
Capacity RNA-to-cDNA kit, pRSET-A vector, Quant-iT Protein Assay Kit, Qubit RNA
Assay Kit.
Millipore; Billerica, MA: cystatin C, Millicell EZ Slide, pepstatin A.
Molecular Research Center, Inc.; Cincinnati, OH: Tri-Reagent RT.
MP Biomedicals; Solon, OH: 5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB).
Promega; Madison, WI: dithiothreitol (DTT), pGEM-T Easy Vector System.
Qiagen; Germantown, MD: E. coli M15, pQE9 vector, pQE30 vector.
Sigma-Aldrich; St. Louis, MO: Bromophenol blue, Coomassie Brilliant Blue R,
Dulbecco’s Modified Eagles Medium (DMEM), JM109 Competent Cells,
ethylenediaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA),
paraformaldehyde, penicillin-streptomycin, PIPES, proteinase K, saponin, sodium azide,
triton-X 100.
Thermo Scientific: 1-Step NBT/BCIP, 6X DNA Loading Dye, DreamTaq PCR Master
Mix, Ethidium Bromide Solution, GeneJet Gel Extraction Kit, GeneJet Plasmid Miniprep
Kit, GeneRuler 1 kb DNA Ladder, Goat Anti Rabbit IgG Fc Alkaline Phosphatase,
HisPur Ni-NTA Resin, lysozyme, Melon Pierce Crosslink Immunoprecipitation Kit,
Phusion Site-Directed Mutagenesis Kit, Recombinant Protein A Agarose, Spectra
Multicolor Broad Range Protein Ladder, TopVision LE GQ Agarose, Tubulin Beta
Polyclonal Antibody (rabbit).
Whatman; Dassel, Germany: Reinforced Nitrocellulose Membrane.
Buffers, Media, and Solutions
Alkaline phosphatase buffer: 100 mM NaCl, 5 mM MgCl 2, 100 mM tris-HCl.
BRBD80: 80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, pH 6.8.
Buffer B: 100 mM NaH2PO4, 10 mM tris-HCl. Adjust pH to 8 using NaOH.
Buffer T: 100 mM potassium phosphate, 2 mM EDTA, pH 7.4.
Calcium chloride solution: 60 mM CaCl2, 15% glycerol, 10 mM PIPES (pH 7).
Autoclave or filter sterilize.
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Genomic DNA (gDNA) lysis buffer: 40 mM Tris-HCl (pH 8), 80 mM EDTA (pH 8), 2 %
SDS, 0.1 mg/mL proteinase K (add just before use).
10 mg/mL insulin: Mix 50 mg bovine insulin in 4 mL 0.5 M tris-HCl (pH 8). Adjust pH
to 2 or 3 using 1 M HCl and then rapidly titrate back to 8 using 1 M NaOH. Add dH2O to
5 mL.
Immunoprecipitation buffer: 50 mM tris-HCl, 100 mM NaCl, 1% triton-X 100, 0.5%
deoxycholic acid, 1% BSA, 0.02% sodium azide, 0.2 mM PMSF, 40 nM cystatin C, 150
nM pepstatin A.
Immunoprecipitation lysis solution: 1% SDS, 100 mM NaCl, 0.2 mM PMSF, 50 mM trisHCl, 40 nM cystatin C, 150 nM pepstatin A.
Immunoprecipitation wash solution: 50 mM tris-HCl, 100 mM NaCl.
Insulin assay buffer: 20 mM EDTA, 100 mM KH2PO4.
Luria-Bertani (LB) medium: 0.5% yeast extract, 1% NaCl, 1% tryptone.
Nycodenz buffer: 300 mg Tris-HCl, 61 mg CaNa2EDTA ∙ H2O, 110 mg KCl (BDH).
Dissolve in 450 mL H2O and adjust pH to 7.5 using 1 M NaOH. Fill to 500 mL and
autoclave. Store at room temperature.
100% Nycodenz: 55.2 g Nycodenz (Axis-Shield). Add powder to 200 mL Nycodenz
buffer. Autoclave and keep at room temperature. Before use, mix with sterile PBS.
PEM buffer: 100 mM PIPES, 1 mM EGTA, 2 mM MgCl2, pH 6.8.
Phosphate-buffered saline, 10X: 1.37 M NaCl, 27 M KCl, 43 mM Na2PO4, 14 mM
KH2PO4.
100X Pyrimethamine Stock Solution (7 mg/mL): 280 mg pyrimethamine, 40 mL DMSO.
Dissolve pyrimethamine in DMSO by vortexing for a few minutes until solubilized. The
stock solution can be kept at room temperature and diluted in drinking water before use.
As the pyrimethamine precipitates when adding water, the pH is lowered by adding HCl
to the water. Pyrimethamine will be resolubilized between pH 3-5.
Reservoir buffer, 10X: 0.25 M tris, 2 M glycine.
Schizont culture medium: 16.4 g RPMI without HEPES, 1.75 g NaHCO3, 25 U/mL
penicillin/streptomycin. Dissolve all ingredients in 900 mL H2O and adjust pH to 7.2. Fill
to 1 L, filter sterilize, aliquot, and store at -20° C.
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SDS electrophoresis buffer: 0.125 M tris, 0.96 M glycine, 0.5% SDS.
SDS-PAGE sample buffer, 2X: 0.09 M tris-HCl (pH 6.8), 20% glycerol, 2% SDS, 0.02%
bromophenol blue.
TAE electrophoresis buffer: 242 g tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 M
EDTA solution (pH 8), H2O to 1 L.
Accession Numbers
PlasmoDB ID numbers for reported genes and proteins are as follows:
Thioredoxin Reductase (PBANKA_082470), Thioredoxin-1 (PBANKA_132090), Trx469/PhLP1 (PBANKA_120480). GenBank (NCBI) ID numbers are as follows: TXNDC9
(NM_005783.3), Thioredoxin (BC003377.1).

Parasite Maintenance and Mosquito Infections
Plasmodium berghei ANKA 2.34 parasites were maintained in Harlan ND4 mice
for a maximum of four serial passages and passed through Anopheles stephensi
mosquitoes.
Cultivation of HepG2 and HeLa Cell Lines
HepG2 cells were provided by Dr. Anwar Khan from University of Illinois at
Chicago, and HeLa cells were provided by Father Peter Breslin from Loyola University
Medical Center. Cells were maintained in DMEM, 10% FBS, 1% penicillin/streptomycin
in a 37° C incubator with 5% CO2.
Generation of Human and P. berghei cDNA
Total RNA from P. berghei or HepG2 cells was extracted using Tri-Reagent
according to manufacturer’s instructions. Isolated RNA was treated with DNAse I and

14
subsequently quantified using the Qubit RNA Assay Kit and the Qubit fluorometer. RNA
samples were either immediately used for cDNA synthesis or flash frozen and stored at 80° C. cDNA was synthesized from total RNA with the High Capacity RNA-to-cDNA
kit using random hexamer primers.
Isolation and Purification of P. berghei gDNA
A 1 mL sample of mouse blood containing ~20% mixed asexual blood stages was
centrifuged at 3000 x g for 2 minutes. The cells were washed once in cold PBS and then
resuspended in 1 mL PBS. Saponin was added to a final concentration of 0.05% and the
sample was gently mixed. Immediately after lysis was observed, the tube was centrifuged
at 6000 x g for 5 minutes. The supernatant was removed and 25 μL of lysis buffer and 75
μL distilled water were added to the pellet. The tube was then incubated at 37° C for 3
hours with intermittent stirring. After this time, 100 μL of distilled water were added
followed by addition of 200 μL of phenol (equilibrated with 0.1 M Tris-HCl [pH 7.0]).
The solution was mixed well and centrifuged at 2000 x g for 8 minutes. The extraction
was performed again with 200 μL of chloroform. 2 μL of RNace-It Ribonuclease
Cocktail were added for 30 minutes at 37° C. The extraction was performed again with
phenol and chloroform as above.
The gDNA was precipitated by adding one tenth volume of 3 M sodium acetate
(pH 5.0) and 2.5 volumes of absolute ethanol. The tube was allowed to sit for 2 hours or
overnight at -20° C. The precipitate was centrifuged at 2000 x g for 30 minutes at 4° C
and then gently washed once with 70% ethanol and dried in a speed-vac. The pellet was
then resuspended in 25 to 100 μL of distilled water, depending on its size.
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Polymerase Chain Reaction (PCR) of Target DNA
All PCR reactions were incubated on the Eppendorf Mastercycler ep gradient S
thermal cycler.
TXNDC9
The region of the human genome coding for Thioredoxin Domain-Containing
Protein 9 (TXNDC9) was amplified using PCR from cDNA obtained from the HepG2
human liver cell line using a forward primer with a 5’ BamHI site and a reverse primer
with a 3’ HindIII site. The primers were as follows:
Forward: 5’ CCGGATCCGAAGCTGATGCATCTGTTGACATG 3’
Reverse: 5’ CCTTTCTTTATACTAAGTCTGAGACTACTACTAATCTTCGAACC 3’
The following reagents: 5 μM forward primer, 5 μM reverse primer, 1:25 diluted cDNA,
1X DreamTaq PCR Master Mix were mixed and brought to a final volume of 20 μL with
nuclease-free H2O. The reaction was incubated on a ThermoCycler on the following
program: initial denaturing at 94° C for 10 minutes, then 35 cycles of denaturing at 94° C
for 30 seconds, annealing at 60° C for 45 seconds, and elongation at 72° C for 1 minute,
with a final elongation at 72° C for 5 minutes.
hTrx
The region of the genome coding for human Thioredoxin was amplified using
PCR from cDNA obtained from the HepG2 human hepatocyte line using a forward
primer with a 5’ BamHI site and a reverse primer with a 3’ Kpn1 site. The primers were
as follows:
Forward: 5’ GGGGATCCGTGAAGCAGATCGAGAGCAAG 3’
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Reverse: 5’ CTTGAAGCCACCATTAATGAATTAGTCTAAGGTACCCC 3’
The following reagents: 5 μM forward primer, 5 μM reverse primer, 1:25 diluted cDNA,
1X DreamTaq PCR Master Mix were mixed and brought to a final volume of 20 μL with
nuclease-free H2O. The reaction was incubated on a ThermoCycler on the following
program: initial denaturing at 94° C for 10 minutes, then 35 cycles of denaturing at 94° C
for 30 seconds, annealing at 60° C for 45 seconds, and elongation at 72° C for 1 minute,
with a final elongation at 72° C for 5 minutes.
PbPhLP1 knockout construct
The primers for the 5’ region had a 5’ ApaI site and a 3’ HindIII site. The primers
for the 3’ region had a 5’ BamHI site and a 3’ XBaI site. The primers were as follows:
5’ Forward: 5’ CC GGGCCC CAATGCCCCCAAAACGAAAACAGAC 3’
5’ Reverse: 5’ CCAAGCTT CGAATCTAAATATTCACATCTCCATGTAG 3’
3’ Forward: 5’ CCGGATCCGGCGGAGATAATTTTTCTGAACAAGC 3’
3’ Reverse: 5’ CC TCTAGA CCTCTTCATGATACCTCGATTCAAAG 3’
The following reagents: 1 μL genomic DNA (gDNA), 1 mM forward primer, 1 mM
reverse primer, 1X DreamTaq PCR Master Mix were mixed and brought to a final
volume of 25 μL with nuclease-free water. One reaction was set up for each primer pair
and incubated in the thermal cycler on the following program: initial denaturating at 94°
C for 10 minutes, then 35 cycles of denaturing at 94° C for 30 seconds, annealing at 56°
C for 45 seconds, and elongation at 65° C for 45 seconds, with a final elongation at 65° C
for 6 minutes.
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Site-Directed Mutagenesis
5’ phosphorylated primers were designed to mutagenize PbPhLP1 using the
Phusion Site-Directed Mutagenesis Kit. The primers were as follows:
PhLP1-C106S Forward: 5’ AGAAATACTACATGGAGATCGGAATATTTAGATTCG
3’
PhLP1-C106S Reverse: 5’ ATAAAAATGACAACATACATTTGTTGAATTTTTAC 3’
Plasmid DNA was used as a template. The reaction was set up using reagents from the
Phusion Site-Directed Mutagenesis Kit as follows: 10 pg template DNA, 10 mM dNTPs,
1X Phusion HF Buffer, 0.5 μM forward primer, 0.5 μM reverse primer, 1 U Phusion
HotStart II DNA Polymerase were mixed and nuclease-free water was added to 50 μL.
The reaction was incubated on the thermal cycler on the following program: initial
denaturing at 98° C for 2 minutes, then 25 cycles of denaturing at 98° C for 15 seconds,
annealing at 60° C for 30 seconds, and elongation at 72° for 2 minutes, with a final
elongation at 72° C for 10 minutes. A ligation was then performed to circularize the
plasmid. The ligation was set up using the following reagents from the Phusion SiteDirected Mutagenesis Kit: 1X Quick Ligation Buffer, 0.5 μL T4 DNA Ligase were mixed
and incubated at room temperature. The ligation reaction was incubated on ice until
transformation.
TA Cloning of DNA Fragments into pGEM Vector
The following reagents from the pGEM-T Easy Vector System II: 1X Rapid
Ligation Buffer, 25 ng pGEM-T Easy Vector, 3 U T4 DNA Ligase, 1.5 μL solution
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containing DNA fragment were mixed and brought to a final volume of 10 μL using
nuclease-free water. The reaction was incubated overnight at 4° C.
Making DH5α and M15 Competent Using CaCl2
Cells were grown in 50 mL LB media (plus 0.1 mg/mL kanamycin for M15) to an
optical density (OD) of 0.15. Optical density was measured at a wavelength of 650 nm
using the Genesys 6 spectrophotometer (Thermo Scientific). The cells were then pelleted
at 3500 g for 10 minutes at 4° C. The supernatant was discarded and the pellet was
resuspended in 10 mL cold calcium chloride solution. The cells were pelleted at 3500 g
for 5 minutes at 4° C. The supernatant was discarded and the pellet was again
resuspended in 10 mL cold calcium chloride solution. The cells were incubated on ice for
30 minutes and then spun down at 3500 g for 5 minutes at 4° C. The supernatant was
discarded and the pellet was resuspended in 2 mL cold calcium chloride solution.
Competent cells were used within 48 hours for transformation.
E. coli Transformation (DH5α, JM109, M15, BL21)
5 μL plasmid was mixed with 25 μL of the competent cells in a 1.5 mL
microcentrifuge tube. The mixture was incubated on ice for 20 minutes and then heat
shocked at 42° C for 20 seconds. The reaction was again placed on ice for 2 minutes
before 500 μL LB media were added. The cells were then incubated in a 37° water bath
for 1 hour. The transformed cells were spread onto plates containing LB, 1.5% agar plus
antibiotics (0.1 mg/mL ampicillin, 0.1 mg/mL kanamycin and ampicillin, or 0.1 mg/mL
ampicillin and 35 μg/mL chloramphenicol). In the case of blue/white screening, plates
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containing LB, 1.5% agar plus 0.1 mg/mL ampicillin, 0.1 mM IPTG, and 20 μg/mL XGal. The plates were incubated overnight in a 37° C incubator.
Restriction Digests
Restriction digests were done using the following enzymes: ApaI, BamHI,
HindIII, KpnI, XBaI. The reactions were set up according to manufacturer’s instructions.
Ligation of Fragments into Vectors
Ligations using vectors other than pGEM were set up using the following
reagents: 1X T4 DNA Ligase Buffer, 1 μL vector, 16 μL DNA fragment, 0.25 U T4 DNA
Ligase. The reaction was mixed and incubated overnight on the Eppendorf Mastercycler
ep gradient S at 16° C.
Protein Expression
M15 or BL21 cells containing appropriate plasmid were grown in LB plus
antibiotic (0.1 mg/mL ampicillin plus 0.1 mg/mL kanamycin for M15, 0.1 mg/mL
ampicillin plus 35 μg/mL chloramphenicol for BL21) in a shaking incubator at 37° C (or
room temperature for expression of TXNDC9). Optical density (OD) was measured at a
wavelength of 650 nm using the Genesys 6 Spectrophotometer (Thermo Scientific) until
an OD of approximately 0.5 was reached. IPTG was added to a final concentration of 1
mM to induce protein expression. Cells were grown overnight at 37° C or room
temperature while shaking.
Protein Purification
The bacterial culture was pelleted by centrifugation at 6000 g for 15 minutes at 4°
C and the media was removed. Cells were then resuspended in Buffer B plus 45 mM
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imidazole, 10 μM PMSF, and 50 μg/mL lysozyme and shaken at room temperature for 1
hour. Bacteria were sonicated 5 times for 45 seconds and iced for at least 45 seconds
between sonications. Cells were then spun down at 35,000 g for 30 minutes at 4° C.
Pellets were discarded and the cell lysate was poured over a Ni-NTA column. 2 mL of
Ni-NTA slurry was used for every 500 mL of bacterial culture. The lysate was slowly
passed through the column so as to provide adequate time for protein to bind to the beads.
The column was then washed and protein was eluted using an imidazole gradient.
Urea Purification
The bacterial culture was pelleted by centrifugation at 6000 g for 15 minutes and
the media was removed. Cells were then resuspended in Buffer B with 8 M urea at 5
mL/g of wet weight. This mixture was incubated for two hours at room temperature, and
then centrifuged at 10,000 g for 30 minutes at 25° C. Cell lysate was poured over a NiNTA column and was allowed to flow through the column at a rate of approximately 1
drop every 5-8 seconds. After lysate had passed through column, 10 mL of Buffer B with
6 M urea was added. This step was repeated with Buffer B with 4 M urea, 2 M urea, and
1 M urea. The column was then washed with 10 mL Buffer U with 10 mM imidazole and
10 mL Buffer U with 50 mM imidazole. Increased concentration of imidazole in Buffer
U were added to elute the protein.
SDS-PAGE
All SDS-PAGE procedures were performed using the Bio-Rad PowerPac Basic
and Mini PROTEAN II (Bio-Rad; Hercules, CA). Samples were loaded onto tris-glycine
gels immersed in 1X SDS electrophoresis buffer. The Spectra Multicolor Broad Range
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Protein Ladder was used to compare protein sizes to known standards. Gels were run at
150 V for approximately 90 minutes.
DNA Electrophoresis
All PCRs and restriction digests were run on a gel consisting of 1% TopVision LE
GQ Agarose in 1X TAE buffer plus 0.5 μg/ml ethidium bromide. For restriction digests,
6X DNA Loading Dye was added to the reactions at a final concentration of 1X.
GeneRuler 1 kb DNA Ladder was used to estimate DNA fragment sizes. The samples
were run on a DNA electrophoresis cell at 120 V for 30 minutes.
Construction of Transgenic P. berghei
Production of Schizonts and Purification
40-80 mL of schizont culture medium were supplemented with 20% Fetal Bovine
Serum (FBS) and gassed with 5% CO2, 3% O2. A mouse of 3-5% parasitemia was bled,
and the blood was mixed with the medium/FBS mixture. The culture was gassed as
above. Schizonts were cultured at 37° C while being gently shaken at 50 rpm for 20
hours. The culture was spun at 500 g, and the supernatant was discarded. The blood was
layered on top of 55% Nycodenz/PBS and centrifuged at 300 g for 35 minutes with
acceleration and deceleration set to 4. The interface containing parasites was transferred
into a separate tube. Medium was added to 10-50 mL and the parasites were washed by
spinning for 10 minutes at 720 g. The supernatant was removed almost fully, and the
schizonts were immediately used for transfection.
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Transfection of P. berghei with Amaxa Electroporation System
2-3 days prior to transfection, a mouse was treated with phenylhydrazine (PH).
The mouse was then bled, and the blood was kept at 37° C until use. For transfection, the
Nucleofector I electroporator (Amaxa Biosystems; Cologne, Germany) and the Human T
Cell Nucleofector Kit (Amaxa Biosystems; Cologne Germany) were used. This method
was developed by Janse et al (Janse et al, 2006). 90 μL of Nucleofector solution were
mixed with 20 μL Amaxa Nucleofector Supplement. 100 μL of this mixture and 1-5 μg of
digested plasmid in 10 μL H2O were added to the schizonts. The suspension was rapidly
transferred to an electroporation cuvette. Electroporation was performed with program
U33. After the ‘OK’ signal appeared, the suspension was mixed with 200 μL of the prewarmed blood. Merozoites were allowed to invade for 20-30 minutes while shaking at
300 rpm and 37° C in the Eppendorf Thermomixed (Eppendorf; Hamburg, Germany).
The parasites were then injected intraperitoneally (i.p.) into a naïve mouse.
Drug Selection
Drug selection was started started 1 day after infection. Sulphadiazine treatment
was applied by giving the mice the drug in drinking water at a concentration of 20 mg/L.
Drug pressure was applied for 3 days. Pyrimethamine can be injected i.p. or given in
drinking water. Here, the drug selection with pyrimethamine was done with drinking
water for 3-4 days. WR99210 was injected i.p.at a concentration of 4 mg/mL
(approximately 10 ng WR99210 per g body weight). 100 μL were given for 3-4 days.
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Insulin Assays
A stock solution of 10 mg/mL was made by mixing 50 mg bovine insulin in 4 mL
0.5 M Tris-HCl (pH 8). The pH was adjusted to 2 or 3 using 1 M HCl and then rapidly
titrated back to 8 using 1 M NaOH. dH2O was added to 5 ml. The working solution
consisted of 1.75 mg/mL bovine insulin in assay buffer. Each assay had a volume of 600
μL and was read on the Genesys 6 spectrophotometer. 450 μL working solution plus 150
μL of 275-500 mM imidazole was used as a blank in each reaction. The concentration of
imidazole in the blank and the control depended on the concentration of the imidazole
that was used to elute the protein being tested in the reaction. For each reaction, the
working solution was incubated for 3 minutes with DTT added to a final concentration of
1.67 mM, 1.16 mM, or 0.833 mM in a cuvette. The absorbance was read at 650 nm. After
3 minutes, 4-20 μM protein was added, and the contents of the cuvette were mixed every
2 minutes to prevent precipitation from interfering with the beam of light. 20 μM BSA or
150 μL imidazole was used in place of recombinant protein in the control reaction. The
reactions were allowed to proceed 30-60 minutes, with readings taken every 30-60
seconds.
Immunoprecipitation of Protein from HeLa Cells
Method 1
The protocol for this method of immunoprecipitation was developed from Kopan
et al (Kopan et al, 1996). HeLa cells were grown to confluence in 60 mm dishes. The
media was removed, and cells were washed three times with 1X PBS. Cells were lysed
using immunoprecipitation lysis solution. After lysis, cellular material was transferred to
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a 1.5 mL microcentrifuge tube. Cellular material was sheared by passing the lysate
through a 21 gauge needle approximately 10 times. The tubes were then spun at 20,000 g
for 15 minutes at 4° C to pellet cell debris. The supernatant was transferred to new 1.5
mL tubes. anti-PbPhLP1 antibodies were added to one tube to a final dilution of 1:600.
Immunoprecipitation buffer was added to a final volume of 2 mL. As a control, only
immunoprecipitation buffer and cell lysate (no antibodies) were added to a second tube.
The tubes were then incubated overnight on a shaker at 4° C.
250 μL of Recombinant Protein A Agarose beads were washed with
immunoprecipitation buffer, and 50 μL bead slurry was added to each tube. The tubes
were incubated for 3 hours at 4° C while shaking, and then briefly centrifuged to pellet
the beads. A bent 28 gauge needle was used to remove liquid from the beads. The beads
were resuspended in 1 mL immunoprecipitation buffer and transferred to a new 1.5 mL
microcentrifuge tube. The beads were then washed once with 1 mL immunoprecipitation
buffer and twice with immunoprecipitation wash solution. After final wash, all the
remaining liquid was removed using bent 28 gauge needle. The beads were resuspended
in 30 μL 2X SDS-PAGE sample buffer and boiled at 95° C for 10 minutes. The liquid
was then run on a tris-glycine gel using the SDS-PAGE method.
Modifications to Method 1
Media was removed and plates were washed three times with 1X PBS. 300 μL
lysis buffer was added to each plate, and lysate from all plates were combined in a single
15 mL tube. Cells were sheared by passing the lysate through a pipette multiple times.
The tube was centrifuged at 12,000 g for 15 minutes at 4° C to pellet cell debris, and the
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supernatant was transferred to a 50 mL tube. 12 mL immunoprecipitation buffer was
added. One day before harvesting cells, 150 μL bead slurry, 1 mL immunoprecipitation
buffer, and anti-PbPhLP1 antibodies added to a final dilution of 1:500 were incubated on
a shaker at 4° C overnight. This mixture was added to the 50 mL tube with the cell lysate,
and the tube was incubated overnight at 4°C while shaking. The tube was centrifuged
briefly to pellet the beads at the bottom of the tube. The supernatant was removed. The
beads were resuspended in 1 mL immunoprecipitation buffer and transferred to a 1.5 mL
microcentrifuge tube. The tube was centrifuged again to collect the beads at the bottom of
the tube, and the supernatant was removed. The resin was washed once with 1 mL
immunoprecipitation buffer and three times with wash solution. After all liquid was
removed, 30 μL SDS loading buffer was added, and the tube was boiled at 95° C for 10
minutes. The liquid was run on a protein gel as before, and the gel was stained with
Coomassie. Bands were sent to be sequenced by mass spectroscopy at the University of
Illinois at Chicago.
Method 2: Pierce Crosslink Immunoprecipitation Kit
Unless otherwise stated, all reagents used were from Pierce Crosslink
Immunoprecipitation Kit. Unless otherwise stated, all centrifugation steps took place at
1000 g for 1 minute.
Antibody cleanup. Anti-PbPhLP1 antibodies were purified from serum using the
Melon Gel IgG Purification Kit following manufacturers instructions.
Binding of antibody to Protein A/G Plus Agarose. 2 mL of 1X Coupling Buffer
was prepared for each immunoprecipitation reaction. The bottle of Protein A/G Plus
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Agarose was gently swirled to obtain an even suspension. 20 μL of resin slurry was
added to a spin column for each reaction. The column was placed in a 1.5 mL
microcentrifuge tube and centrifuged. The flowthrough was discarded. The resin was
washed twice with 200 μL 1X Coupling Buffer. The bottom of the column was gently
tapped on a paper towel to remove excess liquid and the plug was inserted. 10 μg of
antibody was prepared for coupling. The volume of antibody was adjusted to 100 μL with
sufficient ultrapure water and 20X Coupling Buffer to produce 1X Coupling Buffer. This
mixture was added to the spin column, and the screwcap was attached. The column was
incubated on a shaker for 1 hour at room temperature. The bottom plug and cap were
removed, and the column was placed in a collection tube and centrifuged. The resin was
washed once with 100 μL 1X Coupling Buffer and twice with 300 μL 1X Coupling
Buffer. The bottom of the column was tapped on a paper towel to remove excess liquid
and the plug was inserted.
Crosslinking bound antibody. 217 μL DMSO was added to a single tube of DSS
to prepare 10X/25 mM solution. The solution was mixed with a pipette until the DSS was
completely dissolved, and then diluted 1:10 in DMSO to make 2.5 mM DSS. 2.5 μL 20X
Coupling Buffer, 9 μL 2.5 mM DSS, and 38.5 μL nuclease-free water were added to the
column and incubated for 1 hour at room temperature while shaking. The bottom plug
and cap were removed, and the column was placed in a collection tube and centrifuged.
50 μL Elution Buffer was added and the column was centrifuged. The column was
washed twice with 100 μL Elution Buffer and twice with cold IP Lysis/Wash Buffer. The
last wash was left in the column, and the column was stored at 4° C until needed.
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Cell lysis. The culture medium was removed and each dish was washed once with
1X Coupling Buffer. 500 μL ice cold IP/Lysis Wash Buffer was added to the plates, and
the plates were incubated on ice for 5 minutes with periodic mixing. The lysate was
transferred to a microcentrifuge tube and centrifuged at 13,000 g for 10 minutes to pellet
cell debris. The supernatant was transferred to a new tube and protein concentration was
determined using the Quant-iT Protein Assay Kit.
Pre-clear lysate using control agarose resin. For 1 mg lysate, 80 μL Control
Agarose Resin slurry was added to a spin column and centrifuged to remove storage
buffer. 100 μL 1X Coupling Buffer was added to the column, and the column was
centrifuged. 1 mg of lysate was added to the column and shaken at 4° C for 45 minutes.
The column was centrifuged. The column was discarded and the flowthrough was saved.
The protein concentration was measured using the Quant-iT Protein Assay Kit.
Immunoprecipitation. The column containing resin and antibody was
centrifuged to remove IP Lysis/Wash Buffer. 1 mg lysate was added to the column and IP
Lysis/Wash Buffer was added to 500 μL. The column was incubated on the shaker
overnight at 4° C. The bottom plug and screw cap were removed and the column was
centrifuged. The column was washed twice with 200 μL IP Lysis/Wash Buffer. The
column was washed once with 100 μL 1X Conditioning Buffer and then placed in a new
collection tube. 10 μL Elution Buffer was added to the column, and the column was
centrifuged. With the column in the same collection tube, 50 μL Elution Buffer was
added and incubated for 5 minutes at room temperature. The column was centrifuged and
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the flowthrough was collected. The elution steps were repeated as desired for further
samples.
Sample preparation for SDS-PAGE analysis. 5X Lane Marker Sample Buffer
was equilibrated to room temperature and gently mixed by inverting 5-10 times. Sample
buffer was added to elutions to make 1X concentration of sample buffer. DTT was added
to 100 mM and samples were boiled at 95° C for 5 minutes. Samples were allowed to
cool to room temperature before being loaded on gel. Samples were run using the SDSPAGE method. The gel was stained with Coomassie, and bands were sent for sequencing
by mass spectroscopy at the University of Illinois at Chicago.
Modifications to Method 2
Two columns were prepared, one containing lysate, beads, and antibody, and one
containing only antibody and beads. 50 μg of anti-PbPhLP1 antibody was used during
crosslinking, and wash steps were doubled in order to accommodate larger concentration
of protein. The resulting gel was used for a Western blot.
Western Blots
Sample Preparation Using Parasite Lysate
Cryotubes containing 2 mL of flash frozen blood infected with P. berghei was
allowed to thaw at room temperature. Blood was transferred to a 50 mL tube. Cryotubes
were rinsed with 1X PBS and the rinses were added to the 50 mL tube. 1X PBS was
added to a final volume of 20 mL, and the tube was centrifuged at 750 g for 5 minutes.
The supernatant was aspirated and the pellet resuspended in 20 mL 1X PBS. The tube
was centrifuged at 800 g for 10 minutes. The supernatant was removed, cells were
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resuspended in 20 mL 1X PBS, and red blood cells were lysed by adding saponin to a
final concentration of 0.01%. The tube was mixed by inversion for 2 minutes and
centrifuged at 1800 g for 10 minutes. The supernatant was aspirated and the lysis was
repeated. The cells were then resuspended in 20 mL 1X PBS and centrifuged at 1800 g
for 10 minutes. The supernatant was aspirated and the cells were resuspended in 1 mL 1X
PBS and transferred to a 2 mL microcentrifuge tube. PMSF was added to a final
concentration of 60 μM. From this, two 200 μL volumes were transferred to 1.5 mL
microcentrifuge tubes. SDS-PAGE sample buffer was added to a final concentration of
1X. BME was added to 0.75% to one of the tubes. Both samples were boiled at 95° C for
5 minutes and centrifuged at 10,000 g for 10 minutes at 4° C. The samples were then run
using SDS-PAGE.
Sample Preparation Using Recombinant Protein
Desired concentration of protein was used and SDS-PAGE sample buffer was
added to a final concentration of 1X. BME was added to a final concentration of 5%.
Samples were boiled at 95° C for 2 minutes and iced for 2 minutes before being run using
SDS-PAGE.
Sample Preparation Using Purified Tubulin
Purified porcine tubulin and PEM buffer were provided by Dr. Holly Goodson at
Notre Dame University. Tubulin was diluted 1:1 with PEM buffer. SDS-PAGE sample
buffer was added to a final concentration of 1X, and BME was added to a final
concentration of 5%. Samples were boiled at 95° C for 2 minutes and iced for 2 minutes
before being run using SDS-PAGE.
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Transfer from Gel to Nitrocellulose
After electrophoresis, gel was allowed to sit in reservoir buffer for 10 minutes.
Nitrocellulose membrane was also incubated in reservoir buffer during this time. The blot
was assembled and run while submerged in reservoir buffer using the Bio-Rad Mini
Trans-Blot Module (Bio-Rad; Hercules, CA) at 100 V for 1 hour.
Immunofluorescent Staining of Nitrocellulose Membrane
After blotting, the membrane was incubated in blocking buffer (2.5 g milk powder
in 1X PBS) for 20 minutes. Blocking buffer was poured off, and, if necessary, membrane
was cut if different portions were to be stained using different antibodies. Primary
antibodies (rabbit anti-PbPhLP1 or Tubulin Beta Polyclonal Antibody) were diluted using
blocking buffer and added to membrane for one hour while shaking. Membrane was
washed three times with 1X PBS and then placed in 1X PBS on shaker for 15 minutes.
PBS was poured off. The secondary antibody, Goat Anti Rabbit IgG Fc Alkaline
Phosphatase, was diluted using blocking buffer and added to membrane for 1 hour while
shaking. Membrane was washed three times with 1X PBS. PBS was poured off and
BCIP/NBT was allowed to incubate with membrane on shaker until bands started to
appear. BCIP/NBT was then removed and alkaline phosphatase was added until
membrane was just covered. Membrane was incubated in alkaline phosphatase overnight.
Immunofluorescence
Paraformaldehyde/Glutaraldehyde Fixation
Media was removed and cells were washed once with 1X PBS. 3%
paraformaldehyde, 0.25% glutaraldehyde, and 0.2% Triton X-100 in BRBD80 was added
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to cells and allowed to incubate for 15 minutes at room temperature. Supernatant was
removed, and cells were washed with 1X PBS. Cells were permeabilized by adding -20°
C 100% methanol for 10 seconds, and then washed with 1X PBS. 0.5 mg/mL NaBH4 in
1X PBS was added for 10 minutes. Cells were washed three times with 1X PBS before
proceeding to staining.
Glutaraldehyde Fixation
Media was removed and cells were washed with 1X PBS warmed to 37° C.
BRBD80 plus 0.5% Triton X-100 and 2% glycerol was added to cells for 20 seconds.
Glutaraldehyde was added to final concentration of 0.5% and cells were shaken gently for
10 minutes in the solution. The liquid was removed and 0.5 mg/mL NaBH4 in 1X PBS
was added for 7 minutes. Cells were washed three times with 1X PBS and then
permeabilized with 0.1% Triton X-100 in PBS for 15 minutes. Cells were washed again
three times with 1X PBS before proceeding to staining.
Antibody Staining
Cells were blocked for 30 minutes in 0.1% donkey serum in 1X PBS. Cells were
then washed three times with 1X PBS. Primary antibodies (rabbit anti-PbPhLP1, antibeta tubulin monoclonal antibody, or Tubulin Beta Polyclonal Antibody) were diluted in
0.1% donkey serum in 1X PBS and incubated with cells for 1 hour at room temperature
while shaking. Cells were then washed three times with 1X PBS. Secondary antibodies
(Alexa Fluor 555 Goat Anti-Mouse, Alexa Fluor 555 Goat Anti-Rabbit, or Alexa Fluor
488 Goat Anti-Rabbit) were diluted in 0.1% donkey serum in 1X PBS and incubated with
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cells for 1 hour at room temperature while shaking. Cells were washed again three times
with 1X PBS.
Phalloidin Staining
After permeabilization and antibody staining, phalloidin (provided by Dr. Anwar
Khan at University of Illinois at Chicago) was applied at a dilution of 1:60 in 0.1%
donkey serum in 1X PBS for 1 hour at room temperature while shaking. Cells were
washed three times in 1X PBS.
Imaging
Images were acquired on FluoView FV1000 Confocal Laser Scanning
Microscope (Olympus). Images were taken in XY plane and compressed around the Z
axis. AF 488 was excited by exposure at 488 nm, and AF 555 was excited by exposure at
555 nm, with fluorescent emissions were recorded at 530 nm and 565 nm, respectively.
Thioredoxin System Assays
All assays were measured in UV cuvettes using the Genesys 6 spectrophotometer.
Unless otherwise stated, all reactions were carried out in Buffer T at room temperature in
a final volume of 1 mL.
For all thioredoxin assays, absorbance was measured at 340 nm. 200 μM NADPH
and10-40 μM rPbTrx-1 or hTrx were incubated on spectrophotometer to establish a
baseline. 50 nM PbTrxR was added, and the absorbance was read. After the reaction was
completed, the protein to be tested was added, and the absorbance was read.
Alternatively, the experimental protein was added before PbTrx-1.
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Modeling
Comparative models of the PbPhLP1 and hTXNDC9 structures were made using
Swiss Model (http://swissmodel.expasy.org; Arnad et al, 2006). The thioredoxin-like
domain of Homo sapiens Phosducin-Like Protein 2 (PDCL2) (PDBid: 3EVI) was
selected as a template using a protein BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) against the sequences in the
Protein Data Bank. The evolutionary conservation of the structures was investigated
using ConSurf (Ashkenazy et al, 2010). The models were visualized using the VMD
molecular graphics program (Humphrey et al, 1996).
Phylogenetics
Phylogenetic trees were constructed by Dr. Catherine Putonti at Loyola
University Chicago.
Sequence Comparison
The PbPhLP1 and PbPhLP2 amino acid sequences, retrieved from PlasmoDB
(Aurrecoechea et al, 2009) were aligned using EBI’s CLUSTALW2 tool online (Larkin
et al, 2007). The conserved thioredoxin domain (phosducin (Phd)-like family,
Thioredoxin (TRX) domain-containing protein 9 or Phd_like_TxnDC9) was identified
within each sequence via NCBI’s Conserved Domain Database (Marchler-Bauer et al,
2009). The sequence identity between the two sequences was calculated based upon the
CLUSTALW alignment in BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
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Identifying Paralogs and Homologs
The PbPhLP1 and PbPhLP2 amino acid sequences were BLASTed against the
NCBI nr protein database using blastp, retrieving the 1000 best hits given a word size of
two (Altschul et al, 1997). The PbPhLP1 sequence BLAST results all had an e-value less
than 0.002; the PbPhLP2 sequence BLAST results all had an e-value less than 0.037.
The BLAST results were downloaded and parsed, using in-house parsers
developed in C++, producing FASTA format files. Two FASTA format files were
created for the PbPhLP1 and PbPhLP2 searches—the homologous sequences and the
orthologous sequences. The homologous files include all 1000 hits for the individual
BLAST. These files include orthologous sequences as well as paralogous sequences as
there are many copies of the thioredoxin domain within the genomes of all species, not
just Plasmodium. While the vast majority of the sequences returned for the BLAST
searches encompassed more than just the thioredoxin domain, there were several smaller
partial sequences, many of which are annotated as thioredoxins or putative thioredoxins.
The second pair of FASTA files created contained only orthologs of PbPhLP1 and
orthologs of PbPhLP2. The BLAST of the PbPhLP2 sequence against NCBI’s Protein
database identified its paralog, PbPhLP1, with an e-value of 8 x 10-12, 68% coverage, and
32% identity. Using this as our threshold, we restricted orthologs to hits with a coverage
≥ 68% and a sequence identity >32%. 50 orthologs were identified for the PbPhLP2
sequence and 140 orthologs were identified for the PbPhLP1 sequence.
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Deriving Phylogenetic Trees
Phylogenetic trees were created using MEGA 5.05 (Tamura et al, 2011). Within
the MEGA software, the sequences were aligned via CLUSTALW using the default
alignment parameters. All phylogenetic trees were derived using the Maximum
Likelihood method with 100 bootstrap replications. The trees generated were then saved
in NEWICK format and visualized using PhyloWidget (Jordan and Piel, 2008).

CHAPTER III
RESULTS
Preliminary Data
A screen of the Plasmodium genomics database PlasmoDB (Aurrecoechea et al,
2009) for proteins containing a putative thioredoxin domain revealed multiple genes, one
of which was a previously uncharacterized gene of the mouse malaria parasite
Plasmodium berghei which our lab tentatively named pbtrx-469 (previously
PB000469.02.0, now PBANKA_120480). The gene is located on chromosome 12 of the
Plasmodium genome and consists of one exon and no introns (Figure 4). The protein
consists of two domains, a predicted C-terminal thioredoxin domain and an N-terminal
helical domain. The protein sequence lacks any predicted targeting sequence or
transmembrane domain, causing us to hypothesize that PbTrx-469 may be cytosolic. In
addition, while the protein sequence does contain six cysteines, it lacks the classical
CXXC active site. Transcriptome and mass spectrometry data available on PlasmoDB
indicated that pbtrx-469 is expressed during all life stages of the P. berghei life cycle
(Hall et al, 2005).
Initial work performed in our lab to characterize pbtrx-469 included quantitative
real-time RT-PCR (qRT-PCR) to determine the relative expression of the gene (Figure
5a). Expression was examined in blood stages, ookinete cultures, and parasites taken
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from the mosquito midgut, and was compared to expression of P. berghei Thioredoxin-1
(pbtrx-1). The transcript abundance of pbtrx-469 was found to be approximately a
hundredfold lower than that of pbtrx-1 in both blood stage samples and mosquito midgut
samples, and tenfold lower that pbtrx-1 in ookinete cultures (Figure 4a). These results
indicate that pbtrx-469 is expressed at low levels when compared with other genes like
pbtrx-1. In addition, qRT-PCR experiments were completed to examine how the
transcript abundance changes during the time that the parasite is within the mosquito
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midgut (Figure 5b). The mRNA levels at the 6 hour time point were comparatively low
when compared to the profiles of known antioxidant genes (Turturice et al, 2013).

Our lab cloned and expressed PbTrx-469 in a bacterial system. The recombinant
protein was purified, and a band at approximately 24 kDa was observed, consistent with
the calculated size of recombinant PbTrx-469 (Figure 6).
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The purified recombinant protein was then sent out for polyclonal antibody production in
rabbits (Open Biosystems, Thermo Scientific). Upon receipt, the antibody-containing
serum was tested in a Western blot analysis with recombinant PbTrx-469 (Figure 7). The
antibodies produced a prominent band at approximately 24 kDa, suggesting that they
primarily bind to recombinant PbTrx-469. As a control, the antibodies were also tested
with recombinant PbTrx-1 (Figure 7). No interaction was observed.

Immunofluorescent assays (IFAs) were then conducted to determine the
expression pattern and subcellular localization of Trx-469 in P. berghei. The antibodies
were used to stain the protein during different stages of the P. berghei life cycle,
including asexual blood stages such as trophozoites (Figure 8a) and schizonts (Figure
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8b), and mosquito stages such as ookinetes (Figure 8c), and sporozoites (Figure 8d). In
these initial IFA images, it appears that the protein is localized close to the periphery of
the parasite cell (Figure 8a-8d), suggesting that PbTrx-469 may be associated with the
plasma membrane of the parasite. Interestingly, the anti-PbTrx-469 antibodies seemed to
cross-react with components in or close to the membrane of the host red blood cells
(Figure 8e). It was unclear whether this signal was due to an unspecific background
signal or a more specific cross-reaction with a related protein of the mammalian host cell.

While conducting research with our collaborator Dr. Shin-Ichiro in Japan, we
conducted IFAs on human hepatocytes infected with P. berghei sporozoites using
antibodies against several Trx-like proteins, including PbTrx-469. Interestingly, while
anti-PbTrx-1, anti-PbTPx-1, and anti-Pb1CysPrx antibodies were parasite specific, the
anti-PbTrx-469 antibodies seemed to be binding to a protein within the human host cells
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as well (Figure 9). The protein appeared to be associated with the microtubular network
of the host cell.

The objective of this project was to further characterize this novel thioredoxin
domain-containing protein in Plasmodium. Efforts would first be made to characterize
pbtrx-469 using gene knockout experiments. In addition, the presence of the thioredoxin
domain within PbTrx-469 caused us to characterize the protein biochemically. The
second part of this project was to identify what the antibodies may be recognizing in
human cells, and whether or not this target represented a homolog of PbTrx-469.
Disruption of the pbtrx-469 Gene in P. berghei Parasites
To help determine the significance and potential function of PbTrx-469 in the
malaria parasite, I aimed to disrupt, or knockout (KO), the pbtrx-469 gene in P. berghei.
This project was organized into two parts. My first task was to generate a DNA plasmid
or KO construct here at Loyola. The verified construct would then be sent to our
collaborator, Dr. Andrew Blagborough, for transfection into P. berghei parasites. Dr.
Blagborough is a researcher in the laboratory of Dr. Robert Sinden at Imperial College
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London, United Kingdom, and an expert in Plasmodium transfection and gene KO
studies (Talman et al, 2011).
Since Plasmodium is haploid during most of the erythrocytic stages of the life
cycle, it is possible to interrupt the function of a gene through a single targeting event
(Waters et al, 1997). This is achieved through the process of homologous recombination
between a plasmid containing the KO construct and the target gene in the parasite
genome (Janse et al, 2006). In general, there are two different methods for targeting a
gene in this manner, a double crossover knockout (also known as a replacement
knockout) or a single crossover knockout (also known as an insertion knockout) (Ménard
and Janse, 1997). I chose to use the former method to KO pbtrx-469 (Figure 10).
In this method, the construct includes two regions of homology to the gene, and
recombination results in the replacement of the entire gene by the selectable marker
(Ménard and Janse, 1997). In this approach it is impossible for the parasite to regenerate
the wild-type gene. In the single crossover knockout, the construct includes only one
region of homology to the gene, and recombination leads to the insertion of the entire KO
plasmid. In this case, the entire gene is still present in the knockout parasites, however it
is interrupted by a selectable marker. It is therefore possible for the parasite to remove the
selectable marker and reform the wild-type (WT) gene (Ménard and Janse, 1997). I
therefore chose to use the double-crossover method for this project in order to avoid a
reformation of the WT pbtrx-469 gene.
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Generation of the Knockout Construct
I designed PCR primers that amplified two regions of the parasite genome. One
region, the 5’ region, coded for a short stretch of the 5’ UTR as well as the beginning of
the pbtrx-469 gene. The other region, the 3’ region, coded for a short stretch of the 3’
UTR as well as the end of the pbtrx-469 gene (Figure 10). The 5’ region primers were
engineered to contain an ApaI and a HindIII restriction site, and the 3’ region primers
were engineered with a BamHI and a XbaI restriction site. A PCR using genomic P.
berghei DNA as template resulted in two distinct bands, one at approximately 516 base
pairs representing the 5’ region and one at approximately 348 base pairs representing the
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3’ region of pbtrx-469 (Figure 11a). Each DNA fragment was TA cloned into the
bacterial pGEM T Easy vector (Promega). The resulting plasmids were sequenced and
compared to the P. berghei genome sequence (PlasmoDB).
A vector designed for targeted KO in P. berghei, pBS-DHFR (Donald and Roos,
1993) was kindly provided by Dr. Andrew Blagborough (Figure 10). This vector contains
a Dihydrofolate Reductase (DHFR) resistance cassette, which confers resistance to the
antimalarial drug pyrimethamine (Waters et al, 1997). The pBS-DHFR vector also
contains multiple cloning sites for the insertion of DNA. Following sequence verification,
I cloned each region into the pBS-DHFR vector, resulting in the pBS-pbtrx-469-DHFR
KO construct (Figure 10).

The resulting plasmids were sent out for sequencing to verify the accuracy of the
inserts. In parallel, I performed analytical restriction digests to ensure that the plasmid
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was complete (Figure 11b). Bands at approximately 5000 and 3000 bp were observed,
representing the KO insert and the remaining plasmid, respectively. The band at
approximately 8000 bp represented undigested plasmid. I performed a large scale plasmid
prep and determined DNA concentrations using a NanoDrop 2000 Spectrophotometer
(Thermo). I then sent 10 μg of undigested plasmid and 5 μg of ApaI and XBaI digested
plasmid to Dr. Andrew Blagborough for the second stage of this project, the transfection
of the pBS-pbtrx-469-DHFR KO construct into P. berghei parasites.
pbtrx-469KO Parasites Are Not Viable
As mentioned, Dr. Andrew Blagborough at Imperial College London transfected
parasites with the KO construct. After experiments were completed, he provided us with
a brief description of his results. Linearized KO plasmid was transfected into purified P.
berghei schizonts by electroporation using the Nucleofector I electroporator (Lonza AG).
Transfected parasites were then injected intraperitoneally (IP) into naïve BLAB c mice.
Drug selection with pyrimethamine was started one day after injection. Only transfected
parasites that received and maintained the KO plasmid should be able to survive under
drug pressure. Drug pressure was maintained for 3-4 days, after which time mice were
checked for the presence of parasites. No parasites were observed following the first
transfection. Three additional transfections were attempted with the same result. It was
concluded that pbtrx-469 is likely essential for asexual parasite development.
Biochemical Characterization of PbTrx-469
The results from the gene knockout experiments suggested that pbtrx-469 is
essential for P. berghei. Yet this extreme phenotype did not allow me to draw any
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conclusions about the purpose this gene serves for the parasite. Since PbTrx-469 had
previously been cloned and expressed by our lab, I decided to characterize this protein
biochemically in order to determine whether or not the Trx domain was important for its
function.
Some thioredoxin and thioredoxin-like proteins reduce substrate proteins through
the process of cysteine-thiol disulfide exchange (Nickel et al, 2006). The insulinreduction assay, established by Arne Holmgren (Holmgren, 1979), is a test to determine
whether or not a protein possesses redox activity. This assay tests whether the protein is
able to catalyze the reduction of the disulfide bonds between the A and B chains of
insulin by the redox reagent dithiothreitol (DTT). Reduction of these bonds leads to the
precipitation of the two chains. The resulting turbidity of the assay solution can be
quantified using a spectrophotometer.
PbTrx-469 Reduces Insulin in the Insulin-Reduction Assay
Six or eight µM recombinant PbTrx-469 (rPbTrx-469) was incubated with 1 mM
DTT and 26.4 μg bovine insulin in assay buffer. rPbTrx-1 was used as a positive control
(Kanzok et al, 2000). A second control containing only DTT and insulin was also used.
The reaction was run for 45 minutes. The results show that 6 μM rTrx-469 catalyzes the
reduction of insulin at a rate of 0.0038 A/min (Figure 12). Increasing the concentration of
rPbTrx-469 to 8 μM resulted in a 1.8 fold increase in the insulin reduction rate. As
expected, 8 μM rPbTrx-1 efficiently reduced insulin at a rate of 0.054 A/min. In contrast,
no significant reduction was observed in the absence of either rPbTrx-469 or rPbTrx-1
during the time frame of the experiment. These results indicate that PbTrx-469 is redox
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active. In addition, since the redox activity of thioredoxin-like proteins is dependent upon
cysteine residues, I hypothesized that at least one of the cysteine residues identified in the
primary sequence of PbTrx-469 is redox active and part of the putative active site.

PbTrx-469 Exhibits Redox Activity with the Thioredoxin System
Redox activity of PbTrx-469 in the insulin-reduction assay only indicates the
presence of peroxidatic cysteines within the protein. The next step was therefore to test
whether PbTrx-469 is reduced by the thioredoxin system, a vital part of the cellular redox
network. Testing PbTrx-469 with its endogenous thioredoxin system would provide
better information on its potential biochemical and cellular functions.
The thioredoxin system consists of the flavoprotein thioredoxin reductase (TrxR)
and the small redox active protein thioredoxin (Trx) (see Introduction, Figure 2). In
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addition to cloning and expressing rPbTrx-1, our lab has also recently cloned and
expressed rTrxR of P. berghei (Turturice et al, 2013) and established the redox activities
of both enzymes in a thioredoxin assay (Kanzok et al, 2000; Haselton et al, 2014).
PbTrxR utilizes electrons from the universal electron carrier NADPH reduce oxidized
PbTrx-1 (Kanzok et al, 2002). Since NADPH, but not NADP+ exhibits an absorbance at
340 nm, the oxidation of NADPH to NADP+ can be measured as a decrease in
absorbance using a UV spectrophotometer.

Using the thioredoxin reduction assay, I tested whether or not PbTrx-469 can be
reduced by its endogenous thioredoxin system. If PbTrx-469 accepts electrons from the
thioredoxin system, I should observe a decrease in absorbance indicating that electrons
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flow from the thioredoxin system to PbTrx-469. An assay was set up in a 1 mL cuvette
containing 200 μM NADPH and 20 μM PbTrx-1. The absorbance was measured at 340
nm, giving a reading of 1.45 A, which was in the expected range for the concentration of
NADPH used. No change in absorbance was detected as the reaction was allowed to
baseline. After 2 minutes, rPbTrxR was added to the assay to a final concentration of 50
nM. As expected, a rapid decrease in absorbance was observed, indicating that rPbTrx-1
was readily reduced by rPbTrxR at a rate of 29.5 μM min-1 (Figure 13). The decrease in
absorbance ended after all PbTrx-1 was reduced. I then added rPbTrx-469 to the reaction
at a final concentration of 10 μM. The system resumed NADPH consumption with an
initial rate of 6.5 μM min-1 (Figure 13).
I next wanted to determine whether PbTrx-469 was reduced by PbTrxR or PbTrx1. To determine this, I repeated the experiment by starting the assay with a mix of 200
μM NADPH and 10 μM rPbTrx-469. After 2 minutes of baseline I added 50 nM TrxR.
No significant reduction was observed (Figure 13, open circles). After four additional
minutes I added 20 μM rPbTrx-1 and observed an immediate rapid decrease in NADPH
absorbance, indicating that PbTrx-469 accepts electrons from PbTrx-1 but not from
PbTrxR.
To determine the kinetics of the reaction between PbTrx-1 and PbTrx-469, I performed
additional experiments and varied the concentration of PbTrx-1 between 10-40 μM while
keeping the concentration constant at 10 μM. The kinetic analysis revealed that PbTrx-1
exhibits a KM of 7.3 μM and a kcat of 1 min-1 at a PbTrx-469 concentration of 10 μM
(Figure 14).
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Modeling of PbTrx-469
Redox activity of Trx-like proteins depends on the strategic position of cysteine
residues in the three-dimensional structure of the protein (see Introduction, Figure 3).
Since the insulin-reduction assay and thioredoxin reduction assay both confirmed that
PbTrx-469 is redox active, and since this activity requires at least one cysteine residue
(Holmgren, 1979), the next step was to determine the redox active cysteine and propose a
putative active site for the protein. In collaboration with Ligin Solamen from Dr. Kenneth
Olsen’s laboratory in the Department of Chemistry we generated a hypothetical model of
PbTrx-469 based on the structure of the related human Phosducin-Like Protein 2
(hPDCL2) (PDBid: 3EVI; Lou et al, 2009) (Figure 15).
This model suggests that the thioredoxin domain of PbTrx-469 consists of five
beta strands that form a central beta sheet, surrounded by three alpha helices. In addition,
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a putative active site is present at the N-terminal side of helix 2 in the form of a Thr-ArgTrp-Cys motif. This position coincides with the position of the Cys-Gly-Pro-Cys motif
found in classical thioredoxin proteins (Kanzok et al, 2002). Notably, the position of
Cys106 of PbTrx-469 corresponds to that of the second cysteine in thioredoxin. In
constrast, Thr103 takes the place of the first cysteine in the structure of Trx.

Role of Cys106 in Redox Activity of PbTrx-469
To test whether Cys106 in PbTrx-469 is indeed the redox active cysteine, I
performed site-directed mutagenesis and mutated Cys106 to a serine (C106S) (Figure
16). I hypothesized that if Cys106 is redox active, its mutation to a serine should result in
a significant reduction of redox activity.
Design of mutagenesis primers and cloning of PbTrx-469C106S. Using the
pQE9-PbTrx-469 expression plasmid as template, I designed two tail-to-tail 5’

52
phosphorylated primers. The forward (Fwd) primer introduced two point mutations in the
codon, thereby changing a TGT (Cys) to a TCG (Ser). Using the Phusion Site-Directed
Mutagenesis Kit (Thermo), I performed a PCR that produced a single band at the
expected size of 4000 bp, representing the linearized pQE9-PbTrx-469C106S expression
plasmid. The plasmid was ligated and transformed into competent DH5α cells for
sequencing. It was verified that the two mutations were successfully introduced into the
new expression plasmid. Confirmed pQE9-PbTrx-469C106S plasmids were then
transformed into M15 expression cells (Qiagen) for subsequent protein expression as
described in Materials and Methods.

Expression and purification of PbTrx-469C106S. M15 cells selected for pQE9PbTrx-469C106S were grown in 1 L LB containing ampicillin and kanamycin. Protein
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expression was induced via IPTG and recombinant PbTrx-469C106S was purified as
described in Materials and Methods. A liter of bacterial culture typically yielded 1-2 mg
of PbTrx-469C106S protein. An analytical SDS gel showed a prominent band at
approximately 24 kDa, which is consistent with the previously purified wild-type PbTrx469 as well as the calculated molecular weight of 24 kDa (Figure 17). Another band
observed at approximately 10 kDa was assumed to represent proteolysis products.

PbTrx-469C106S shows significantly reduced redox activity in the insulin
reduction assay. Following purification, I first tested potential redox activity of PbTrx469C106S in the insulin-reduction assay. To this end, I incubated 20 μM PbTrx-469C106S
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with 8 mM DTT and 0.79 mg insulin in assay buffer. In a separate assay I used 20 μM
wild-type PbTrx-469 instead of PbTrx-469C106S (Figure 18). As expected, 20 μM PbTrx469 effectively reduced insulin with a rate of reduction of 0.01 A/min for this assay. The
insulin reduction activity of PbTrx-469C106S was significantly reduced compared to the
wild-type protein, with a rate of reduction of 0.002 A/min. These results indicate that
Cys106 in PbTrx-469 is redox active, supporting my hypothesis that it is part of the
putative active site.

PbTrx-469C106S is also inactive in the thioredoxin system. I next aimed to
determine whether this mutation would also impact electron transfer between rPbTrx-1
and PbTrx-469. Two assays were conducted in parallel, one using rPbTrx-469 and one
using rPbTrx-469C106S (Figure 19). I set up two cuvettes, each containing a mix of 200
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μM NADPH and 40 μM rPbTrx-1. rPbTrxR was then added to each cuvette to a final
concentration of 50 nM. In each reaction, rPbTrx-1 was rapidly reduced by rPbTrxR at an
initial rate of 35 μM min-1. The reactions were followed to completion. I then added 20
μM rPbTrx-469 to the control cuvette and 20 μM rPbTrx-469C106S to the experimental
cuvette. In the assay containing rPbTrx-469, NADPH consumption resumed at an initial
rate of 3.38 μM min-1 (Figure 19). In contrast, no significant NADPH consumption was
observed in the assay containing rPbTrx-469C106S, supporting my hypothesis that C106 is
involved in the catalytic mechanism of PbTrx-469.
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Majority of PbTrx-469 Expressed in E. coli is Insoluble
Purification of PbTrx-469 involved lysing the bacteria that expressed the protein,
pelleting the bacteria, and then running the lysate through a Ni-NTA column in order to
purify the recombinant protein (see Materials and Methods). Theoretically, the majority
of the recombinant protein should be present in the lysate. However, in some cases high
level recombinant protein expression in E. coli may cause the bacteria to form insoluble
protein aggregates known as inclusion bodies (Hartley and Kane, 1988). When this
occurs, the protein aggregates must be solubilized from the bacterial pellet, and the
proteins refolded.
An SDS-PAGE analysis of the bacterial pellet from purification of PbTrx-469
showed strong bands at the expected molecular weight of the recombinant protein,
suggesting that significant amounts of PbTrx-469 may be insoluble and kept in inclusion
bodies. A literature review revealed that researchers working on related proteins had
encountered similar problems and had used denaturing conditions to extract the protein
from the inclusion bodies (Stirling et al, 2006). To achieve a better yield of recombinant
PbTrx-469, I therefore used a urea purification method when producing the protein (see
Materials and Methods). This method allows for dissolution of the inclusion bodies by
destroying all non-covalent interactions. The subsequent and careful removal of the urea
then allows for the refolding of the recombinant protein.
SDS-PAGE analyses of elutions collected using our original purification method
revealed the presence of multiple bands in addition to the band representing PbTrx-469
(Figure 20a). Thus, we predicted that the urea purification method would also allow for a
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better removal of bacterial contaminants. Kinetics of the PbTrx-469 purified under the
original conditions are also shown (Figure 20a). An SDS-PAGE analysis of urea purified
PbTrx-469 showed fewer bands as well as a higher concentration of protein around the 24
kDa mark (Figure 20b). Enzyme kinetics conducted using urea purified PbTrx-469
showed a lower KM value, confirming our prediction that the urea purification method
produced a protein sample that was both purer and more concentrated.
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Characterization of Homologs of PbTrx-469
IFA Studies Indicate that Anti-PbTrx-469 Antibodies Recognize a Protein
Associated with the Cytoskeleton in Human Cell Lines

The results obtained from previous immunofluorescence assays (IFAs) suggested
that antibodies raised against the P. berghei protein Trx-469 may cross-react with one or
several proteins in the human host cells (see Figure 8). To verify this, I cultured HepG2
cells as well as HeLa cells. After the cells were fixed using glutaraldehyde (see Materials
and Methods), I performed double-labeling with anti-PbTrx-469 antibodies and either
anti-beta tubulin antibodies or phalloidin, which labels actin. Cells were analyzed using
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confocal microscopy (Figure 21). In HepG2 cells, the anti-beta tubulin antibodies clearly
labeled the microtubule network (Figure 21a). The anti-PbTrx-469 antibodies labeled a
target that seemed to be very closely associated with microtubules, since the merged
images show a high degree of overlap between the two labeled proteins (Figure 21a).
The phalloidin stain clearly labeled the actin network (Figure 21b), however, no
significant overlap was observed between the actin network and the target recognized by
the anti-PbTrx-469 antibodies (Figure 21b). Similar results were observed in the HeLa
cells (Figure 21c-f). The staining of the anti-PbTrx-469 antibodies seemed to be
associated with the microtubular (Figure 21c-e) but not the actin (Figure 21f) network. In
all IFAs, it appears that the anti-beta tubulin and anti-PbTrx-469 stain colocalize. In
contrast, the anti-PbTrx-469 stain and phalloidin stain only colocalized weakly, if at all.
Phylogenetic Analysis Reveals High Conservation of PbTrx-469 in Eukaryotcs
A cross-reaction such as the one observed in the IFA may be due to the presence
of a conserved protein in the two organisms. I hypothesized that the anti-PbTrx-469
antibodies may be recognizing a homolog of PbTrx-469 in human cells. To test whether
this may be true, a phylogenetic analysis was performed with Dr. Catherine Putonti. The
amino acid sequence of PbTrx-469 was retrieved from PlasmoDB and compared with the
NCBI non-redundant (nr) protein database using blastp (Altschul et al, 1997) (Figure 22).
The BLAST results revealed that homologs of PbTrx-469 are present in most eukaryotes,
including organisms such as Homo sapiens, Xenopus laevis, Danio rerio, Drosophila
melanogaster, Schistosoma mansoni, and Arabidopsis thaliana (Figure 22b). The degree
of sequence similarity between PbTrx-469 and its homologs varied, with some homologs
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showing identities as high as 38% in Homo sapiens or 41% in Arabidopsis thaliana
(Figure 22c).
This alignment was used to generate a phylogenetic tree (Figure 22a)
demonstrating the relationship between PbTrx-469 and its orthologs in eukaryotic
organisms. Some of these homologs (in humans, Dictyostelium discoideum, Ciona
intestinalis, and others) were annotated as phosducin-like proteins. These results caused
us to change the annotation of PbTrx-469 to Phosducin-Like Protein 1 (PhLP1) in the
Plasmodium database PlasmoDB (Putonti et al, 2013).
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Interestingly, an analysis of the corresponding literature revealed that homologs
of PbPhLP1 are hypothesized to be either directly or indirectly associated with the
cytoskeleton in other eukaryotic organisms including C. elegans (Ogawa et al, 2004),
Arabidopsis thaliana, and humans (Stirling et al, 2006). These reports strengthened our
hypothesis that the anti-PbPhLP1 antibodies may cross-react with a protein associated
with microtubules in human cells.
The BLAST results included the human homolog, called Thioredoxin DomainContaining Protein 9 (hTXNDC9), which shares >50% amino acid identity with
PbPhLP1 within the thioredoxin domain. I hypothesized that it is very likely that the antiPbPhLP1 antibodies cross-react with hTXNDC9 in the HeLa and HepG2 cell lines
(Figure 21). It might therefore be possible to immunoprecipitate hTXNDC9 from HeLa
cells using the anti-PbPhLP1 antibodies.
Immunoprecipitation to Determine the Target(s) of Anti-PbPhLP1 Antibodies in
Human Cells
I performed immunoprecipitation experiments in order to determine the
identitities of any proteins recognized by the anti-PbPhLP1 antibodies in human cells. In
this technique, antibodies are used to isolate a protein from a solution such as a cell lysate
(Bonifacino et al, 2001). To this end, the antibodies are attached to a substrate, such as a
bead, and then incubated with the cell lysate. Any proteins recognized by the antibodies
should bind, while all other proteins flow past. The protein or antibody-protein complex
can then be eluted, or immunoprecipitated, separated using SDS-PAGE, and
subsequently identified using mass spectrometry.
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For this experiment, anti-PbPhLP1 antibodies were incubated with HeLa cell
lysate and Recombinant Protein A Agarose beads, which have a high affinity for the
constant region of the heavy chain of IgG type antibodies (Kopan et al, 1996). A tube
containing only cell lysate and beads, but no antibody, was used as a negative control.
Once the protein elutions were run on SDS-PAGE, this control would allow me to
distinguish between bands resulting from background and bands resulting from
immunoprecipitation by the antibody.
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The Coomassie stained SDS-PAGE gel of a representative immunoprecipitation
experiment is shown (Figure 23). In both the lanes containing the cell lysate sample and
the negative control, a prominent band was observed around the 50 kDa mark and was
hypothesized to represent the heavy chain of IgG (Figure 23, lane 1 and 2). A previous
report had suggested a molecular weight of 26.5 kDa for human TXNDC9 (Stirling et al,
2006). Therefore I hypothesized that a band I observed around the 25 kDa mark may be
hTXNDC9 (Figure 23, lane 1). A second band around the 50 kDa mark was present in the
lane containing the cell lysate sample (Figure 23, lane 1). This band potentially
represented a protein dimer that was immunoprecipitated. I excised both the 25 kDa band
as well as the second 50 kDa band and sent them to the University of Illinois at Chicago
to be analyzed by mass spectrometry. The analysis revealed that both bands consisted of
IgG chains, with the 50 kDa band representing the heavy chain and the 25 kDa band
representing the light chain. However, no proteins other than IgG were detected.
I concluded that the high amount of free antibody in the elutions was preventing
the detection of bound protein in the pull down. I therefore tested a Crosslink
Immunoprecipitation Kit (Pierce) for my subsequent immunoprecipitation experiments.
In principle, this kit first irreversibly crosslinks the antibodies to the Recombinant Protein
A Agarose beads before the cell lysate is added. Unbound antibodies are removed by
washing before the sample cell lysate is added. After antibodies have bound to their
respective target proteins, an elution buffer is then added, causing the protein to be
released from the beads. The goal is to minimize the amount of unbound IgG present in
the elutions.
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I repeated my previous experiment with the experimental tube containing cell
lysate and anti-PbPhLP1 antibodies crosslinked to beads. The control tube contained only
beads and crosslinked anti-PbPhLP1 antibodies. The elutions were split between two
separate SDS gels so that one gel could be used for a Western blot and the other gel for
Coomassie staining, potential band excision, and subsequent mass spectrometry analysis.
For the Western blot, samples and controls were run in duplicates for subsequent
immunoblotting with either anti-PbPhLP1 antibodies or anti-beta tubulin antibodies.
Proteins were separated using SDS-PAGE and then transferred to a nitrocellulose
membrane (Figure 24). A band at approximately 50 kDa appeared in all four lanes. I
concluded that this band corresponds to the IgG heavy chain (Figure 24, lanes 1-4). A
band observed at 25 kDa was assumed to represent the IgG light chain (Figure 24, lane 23). I also observed several bands in the lane containing the immunoprecipitation sample
and that had been incubated with anti-PbPhLP1 antibodies (Figure 24, lane 3). A band
seen just below the 50 kDa mark was assumed to be a potential dimer of hTXNDC9. A
band appearing at approximately 34 kDa was also identified as a potential protein of
interest and was sequenced (Figure 24, lane 3). A band at 55 kDa, which correlates with
the molecular weight of both α- and β-tubulin, was present in both experimental lanes and
was sequenced, since we hypothesized that tubulin may also be present in the pull down
due to an interaction between hTXNDC9 and tubulin (Figure 24, lanes 2 and 4). The
band appearing just below the 25 kDa mark in the Western blot was not visible by
Coomassie stain and was therefore not sequenced (Figure 24, lane 3). The mass
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spectrometry analysis reported that again IgG was the only detectable protein in all
bands.

I consulted the troubleshooting guide of the immunoprecipitation kit, and a
number of possible solutions were proposed. First, when antibody is detected with the
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eluted protein, this may be due to antibodies that were not crosslinked and not removed
effectively. Increasing the number of wash steps should help improve this issue. Second,
it may also be possible that insufficient amounts of the material used to crosslink the
antibodies were added. I planned to implement both of these approaches in subsequent
experiments.
However, while these experiments were being conducted, a review of previous
data (Figure 21) raised the possibility that the anti-PbPhLP1 antibodies may be crossreacting with tubulin. My IFA analysis in human cells had suggested a potential
association between microtubules and the protein recognized by the anti-PbPhLP1
antibodies. However, my SDS gel analysis of parasite isolates (Figure 27) and
immunoprecipitation experiments suggested that the anti-PbPhLP1 antibodies may
potentially cross-react with tubulin, which could also explain the staining pattern
observed in my IFA images (Figure 21).
Anti-PbPhLP1 Antibodies Cross-React with Tubulin
I sent my IFA images to Dr. Holly Goodson, a biochemist at Notre Dame
University who is an expert on microtubules (Margolin et al, 2012), for her evaluation.
She suggested that I test for a cross-reaction between the anti-PbPhLP1 antibodies and
tubulin using a Western blot. She generously provided me with purified porcine tubulin
for this purpose.
A Western blot was performed using recombinant PbPhLP1 and porcine tubulin
in order to test for the presence of anti-tubulin antibodies in the serum obtained from
Open Biosystems, the company that generated the antibodies against our recombinant
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PbPhLP1. Antibody development is usually performed in two separate rabbits. Therefore
I tested the sera from both rabbits to determine if a contamination with anti-tubulin
antibodies occurred in both antibody samples.
15.8 μg of purified tubulin were transferred onto three lanes of nitrocellulose. The
lanes were separated and immunoblotted with the anti-PbPhLP1 antibodies from one
rabbit (Figure 25, lane 4), the anti-PbPhLP1 antibodies from the second rabbit (Figure 25,
lane 5), or the anti-beta tubulin antibodies (Figure 25, lane 3). 0.85 μg of recombinant
PbPhLP1 were transferred onto another two lanes of nitrocellulose and separately
immunblotted with both sets of anti-PbPhLP1 antibodies (Figure 25, lanes 1-2).
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In both lanes containing recombinant PbPhLP1 and immunoblotted with antiPbPhLP1 antibodies (Figure 25, lanes 1-2), a band was observed at approximately 24
kDa, which is consistent with the molecular weight of rPbPhLP1. This verified that the
antibodies, or at least a subset of the antibodies in the sera of each rabbit, detect
PbPhLP1. In the lane containing purified tubulin and blotted with the anti-beta tubulin
antibodies, a band was observed at approximately 55 kDa, which corresponds to the
molecular weight of tubulin (Figure 25, lane 3). A band at approximately 55 kDa was
also observed in both lanes containing purified tubulin that were immunoblotted with the
anti-PbPhLP1 antibodies (Figure 25, lanes 4-5). These results indicate that both sets of
anti-PbPhLP1 antibodies react with rPbPhLP1 (Figure 25, lanes 1-2) as well as tubulin
(Figure 25, lanes 4-5). One explanation may be that the serum samples from both rabbits
were contaminated with anti-tubulin antibodies. An alternative explanation may be that
tubulin and PbPhLP1 share common epitopes that are recognized by the anti-PbPhLP1
antibodies. However, an alignment of PbPhLP1 and P. berghei tubulins showed low
percentages of amino acid identitites ranging from 7% (alpha tubulin) to 18% (delta
tubulin) (Table 1).
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To test the hypothesis that PbPhLP1 and tubulin share a common epitope, I
conducted another Western blot analysis with two samples each of 11.8 μg recombinant
PbPhLP1and 27.5 μg purified tubulin. After transfer to nitrocellulose membrane, the
samples were stained with anti-beta tubulin antibodies (Figure 26).

As expected, a band was observed at ~55 kDa in the lane containing purified tubulin
(Figure 26, lane 1). In the lane containing rPbPhLP1, a band was observed at ~24 kDa,
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consistent with the molecular weight of rPbPhLP1 (Figure 26, lane 3). These results
indicate that PbPhLP1 is also recognized by the anti-beta tubulin antibodies. This
supports the hypothesis that the two proteins may share similar epitopes.
Western Blots of Parasite Lysate

In order to further confirm that the anti-PbPhLP1 antibodies were developed
against PbPhLP1, I also conducted a Western blot containing parasite lysate. Two
samples of P. berghei cell lysate were separated using SDS-PAGE and the resulting gel
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was blotted onto a nitrocellulose membrane (Figure 27). The samples were separated and
each was exposed to either anti-PbPhLP1 antibodies or anti-beta tubulin antibodies.
The banding patterns were compared. The blot that was probed with anti-beta tubulin
antibodies showed a single prominent band at approximately 55 kDa, which corresponds
to the molecular weight of tubulin (Figure 27, lane 1). In contrast, the blot that was
probed with anti-PbPhLP1 antibodies showed two bands at 35 and 50 kDa as well as a
stronger band at approximately 25 kDa (Figure 27, lane 2). We assume that the band at
approximately 50 kDa represents tubulin, which may consist of a mix of parasite as well
as mouse tubulin. It is unlikely that the approximately 25 and 35 kDa bands represent
tubulin as they are not seen in the lane that was blotted with anti-beta tubulin antibodies.
We hypothesize that the 25 kDa band represents PbPhLP1 and that the 35 kDa band
possibly represents mouse APACD, which shares a high homology with hTXNDC9.
However, since we were not able to sufficiently resolve the issue of potential crossreaction of the anti-PbPhLP1 antibodies with tubulin, we decided to use alternative
approaches to investigate potential homologs of PbPhLP1.
Characterization of Human TXNDC9
I still hypothesized that the anti-PbPhLP1 antibodies recognized a homolog of
PbPhLP1 in human cells. It seemed unlikely, given the high degree of identity between
PbPhLP1 and its human homolog (see Figure 22), that the antibodies were only
recognizing tubulin in the HepG2 and HeLa cells. However, I was unable to draw any
conclusions about this hypothetical interaction using either immunoprecipitation or IFA.
To extend our analysis of the human homolog of PbPhLP1 I therefore decided to express
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recombinant hTXNDC9 to test whether the anti-PbPhLP1 antibodies were able to
recognize the human homolog.
Cloning, heterologous expression, and purification of recombinant
hTXNDC9. I designed PCR primers to amplify the open reading frame of human txndc9
(NCBI accession number NM_005783.3) from human cDNA generated from HepG2
cells. The PCR resulted in a single band just below the 700 bp marker. This corresponds
to the calculated size of the txndc9 open reading frame (681 bp) (Figure 28). Following
sequence verification, I cloned the gene into the bacterial pRSETA expression vector.
The six histidines encoded by the pRSETA vector are added to the amino terminus of the
protein, thus allowing the recombinant protein to be purified via a Ni-NTA affinity
column. The resulting plasmid (pRSETA-hTXNDC9) was sequenced and transformed
into BL21-Codon Plus Expression Cells (Agilent).
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Expression of recombinant hTXNDC9 was conducted following the urea
purification protocol and the protein was eluted using an imidazole gradient, as described
in the Materials and Methods. Elutions were size-fractionated using SDS-PAGE (Figure
29). Eluates showed a prominent band at approximately 35 kDa which was assumed to
represent recombinant hTXNDC9.

Anti-PbPhLP1 antibodies cross-react with recombinant hTXNDC9. A
Western blot analysis was performed to determine if anti-PbPhLP1 antibodies cross-react
with recombinant hTXNDC. 13.4 μg of recombinant hTXNDC9 was loaded on a gel.
11.8 μg of recombinant PbPhLP1 and 27.5 μg of purified porcine tubulin were also
loaded as positive controls. The samples were size-fractionated using SDS-PAGE,
transferred onto a nitrocellulose membrane, and probed with anti-PbPhLP1 antibodies
(Figure 30). As observed previously, a single band representing tubulin is visible at
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approximately 55 kDa in the lane containing purified porcine tubulin (Figure 30, lane 1).
A band representing PbPhLP1 appeared at approximately 24 kDa in the lane containing
rPbPhLP1 (Figure 30, lane 3). Smaller bands also appeared in the lane and were assumed
to represent proteolysis products. A band at approximately 35 kDa was observed in the
lane containing recombinant hTXNDC9 (Figure 30, lane 2). This band corresponds to the
Coomassie stained band observed during hTXNDC9 purification and thus strongly
suggests that the anti-PbPhLP1 antibodies cross-react with hTXNDC9.
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This was not surprising as the Plasmodium protein and its human homolog share
55% amino acid identity within the thioredoxin domain (Figure 22c). We also observed
that the blot of purified tubulin with anti-beta tubulin antibodies (Figure 30, lane 1)
exhibited a relatively weak band when compared with the bands in lanes 2 and 3. We
hypothesize that this was due to a deterioration of the purified tubulin sample due to
multiple freeze-thaw cycles.
Conservation of PbPhLP1 active site. While conducting the phylogenetic
analysis of PhLPs (Figure 22), we also investigated whether the homologous proteins
contained the same putative atypical active site (Thr-Trp-Arg-Cys) that I had previously
proposed for PbPhLP1. We found that all of the Plasmodium species as well as the oyster
pathogen Perkinsus marinus contained the same active site motif of Thr-Trp-Arg-Cys
(position 103-106 in PbPhLP1 alignment, Figure 31a). Fifty-six percent of the PbPhLP1
homologs, those in other protozoans, nematodes, insects, and vertebrates, including
human, had a putative active site consisting of [Thr-X-Arg-Cys]. Other frequently
observed and conserved motifs include [Ser-X1-Arg-Cys], [Thr-X1-X2-Cys], [Ser-X1X2-Cys], [X1-X2-Arg-Cys], and [X1-X2-X3-Cys]. The fourth position cysteine was
found to be conserved throughout the 140 PbPhLP1 homologous sequences examined.
Since I had determined that PbPhLP1 is redox active and accepts electrons from
the thioredoxin system (see Figures 12-13), I hypothesized that the presence of this
conserved cysteine motif indicates potential catalytic activity of the homologous proteins.
In collaboration with Dr. Olsen’s lab we generated a hypothetical model of hTXNDC9
based on the previously published crystal structure of hPDCL2 (PDB ID: 3EVI; Lou et
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al, 2009) (Figure 31b). The model shows that Cys104 of hTXNDC9 corresponds to the
second cysteine in thioredoxin in terms of relative position in the structure and therefore
to Cys106 in PbPhLP1 (see Figure 15). This model suggests that Cys104 may be part of a
solvent-accessible active site in hTXNDC9. I therefore decided to test the purified
recombinant protein for redox activity.

Recombinant hTXNDC9 is active in the insulin reduction assay. I first tested
recombinant hTXNDC9 in the insulin-reduction assay. Twenty μM recombinant
hTXNDC9 was incubated with 1.16 mM DTT and 0.78 mg bovine insulin in assay
buffer. 10 μM of PbTrx-1 was used in a separate reaction as a positive control (Kanzok et
al, 2000). 20 μM PbPhLP1 was also used as a positive control. 20 μM BSA was used as a
negative control (Figure 32). As previously observed, both PbTrx-1 and PbPhLP1 were
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able to catalyze the reaction between DTT and insulin, with rates of 0.455 A/min and
0.03 A/min, respectively (Figure 32). No significant reduction occurred in the presence of
BSA. Recombinant hTXNDC9 was also able to reduce insulin at a rate of 0.033 A/min
(Figure 32). These results demonstrate that hTXNDC9 effectively catalyzes the reaction
between DTT and insulin.

Thioredoxin reduction assay. After observing that hTXNDC9 possesses redox
activity, the next step was to determine if this protein is able to accept electrons from the
thioredoxin system. Human Thioredoxin (hTrx) was also expressed and purified for this
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purpose. The oxidation of NADPH to NADP+ by the thioredoxin system was measured at
340 nm using the Genesys6 UV-VIS Spectrophotometer (Thermo).

Two hundred μM NADPH and 10 μM hTrx were incubated in a cuvette. The
reaction was started when rPbTrxR was added to a final concentration of 50 nM.
Recombinant hTrx was rapidly reduced by rPbTrxR (Figure 33). The reaction was
followed to completion. After the reaction came to an end, hTXNDC9 was added to a
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final concentration of 10 μM. The system resumed NADPH consumption with an initial
rate of 7.7 μM min-1 (Figure 33). These results provide evidence that hTXNDC9 is acting
like a true member of the thioredoxin system as it is redox active and can receive
electrons from thioredoxin.

CHAPTER IV
DISCUSSION
The purpose of this study was to characterize a novel Trx domain-containing
protein, known initially as Trx-469, of the rodent malaria parasite Plasmodium berghei.
In our phylogenetic study, we have identified homologs of Trx-469 in most eukaryotic
organisms (Putonti et al, 2013). Homologs in Homo sapiens, Dictyostelium discoideum,
Ciona intestinalis, and others were annotated as phosducin-like proteins. Since the
nomenclature used for these proteins is oftentimes confusing, a table identifying these
proteins has been included for the sake of clarity (Table 2).

Due to the high homology with proteins of the phosducin-like family of proteins
we designated Trx-469 as Plasmodium berghei Phosducin-Like Protein 1 (PbPhLP1),
since it is the first phosducin-like protein to be identified in Plasmodium. We identified
two additional PhLPs within the Plasmodium genome. However, this project focuses on
the experimental characterization of PbPhLP1. In response to our publication, the
80
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Plasmodium database PlasmoDB has reannotated orthologs of PbPhLP1 from putative
thioredoxins to putative phosducin-like proteins in all Plasmodium species.
In addition to its high level of conservation among eukaryotes, my results also
suggested that this gene may play an essential role in the malaria parasite. Four
successive attempts to knockout (KO) phlp1 in P. berghei did not produce viable
parasites. This strongly suggests that this gene is essential for blood stages of the malaria
parasite. This is in contrast to studies in the amoeba Dictyostelium discoideum where the
disruption of PhLP3 had no effect while the knockout of PhLP1 caused impairment of G
protein signaling and the knockout of PhLP2 was lethal (Blaauw et al, 2003). However,
in other organisms RNAi and siRNA knockdown, which, in contrast to a genetic
knockout, targets mRNA to reduce the product of a gene rather than completely removing
it, led to significant cellular defects. For example, RNAi knockdown of C. elegans
C05D11.3 caused abnormal microtubules and defects in cytokinesis (Ogawa et al, 2004).
Similar results were obtained from RNAi studies of Arabidopsis thaliana PhLP3
(Castellano and Sablowski, 2008), while siRNA knockdown of mammalian PhLP3
resulted in an elongation of cells and nuclei due to alterations in the cytoskeletal network
(Hayes et al, 2011). The results of these studies suggest that siRNA or RNAi may
provide more insight into the function of phlp1. However, since RNAi studies are not
possible in Plasmodium (Baum et al, 2009), other methods are necessary in order to
explore potential roles for this protein in the parasite.
We decided to characterize this protein biochemically due to the presence of the
thioredoxin domain in the sequence. My insulin-reduction assay shows that recombinant
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PbPhLP1 effectively catalyzes the reduction of insulin by DTT, indicating the presence
of at least one redox active cysteine (Holmgren, 1979). PbPhLP1 is the first member of
the phosducin-like family of proteins that has been demonstrated to be redox active.
While homologs of PbPhLP1 have been expressed by other researchers, the experiments
conducted in these studies have focused more on the function of the protein at the cellular
level. Human TXNDC9 has previously been expressed as a fusion protein to investigate
protein-protein interactions with the chaperonin containing TCP-1 (CCT) in vitro
(Stirling et al, 2006). However, this research marks the first time that an enzymatic
activity has been demonstrated for any member of the phosducin-like family of proteins.
Although the insulin assay indicates redox activity, it is only useful as an artificial
in vitro assay to detect the presence of redox active cysteines in a protein. Significantly,
PbPhLP1 also shows activity in the thioredoxin-reduction assay. More specifically, I
demonstrated that electrons are passed between PbTrx-1 and PbPhLP1, making PbPhLP1
a potential target for PbTrx-1 in vivo. This activity was observed for proteins purified
under both native and denaturing conditions, indicating that denaturing conditions had no
adverse effects on the activity of the protein. Furthermore, the kinetic data of native and
urea purified PbPhLP1 showed a KM value of 7.26 μM with PbTrx-1, a value that is
highly comparable to KM values of Plasmodium Trx-1 with other Trx-like proteins
(Nickel et al, 2006).
An examination of the amino acid sequence of PbPhLP1 revealed that this protein
contains six cysteine residues in its primary sequence. Of these residues, only the
cysteine present at position 106 in PbPhLP1 was conserved in all organisms included in
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our phylogenetic analysis (Putonti et al, 2013). Furthermore, our hypothetical model of
PbPhLP1 in combination with the sequence analysis indicated that Cys106 may be part of
a putative TXXC active site that occupies a solvent-accessible position in PbPhLP1. This
putative TXXC active site is in the same relative position in the predicted threedimensional structure as the CXXC active site of Trx, with Cys106 corresponding to the
C-terminal cysteine in Trx while Thr103 occupies the position of the N-terminal cysteine.
Site-directed mutagenesis of Cys106 significantly reduced the redox activity of PbPhLP1
in the insulin-reduction assay as well as in the thioredoxin-reduction assay, indicating
that Cys106 is involved in the redox activity of PbPhLP1. This also supports my
hypothesis that this cysteine belongs to the putative active site which we proposed
(Putonti et al, 2013).
This putative TXXC active site within the thioredoxin domain is highly conserved
in PbPhLP1 homologs in protozoans, nematodes, insects, and vertebrates, including
human TXNDC9 (Putonti et al, 2013). While PbPhLP1 possesses six cysteine residues in
its structure, sequence analysis showed that hTXNDC9 possesses only three. Yet our
hypothetical model of hTXNDC9 placed the conserved cysteine (Cys104) at the same
position as Cys106 in PbPhLP1 and the C-terminal cysteine in Trx. We therefore
hypothesized that hTXNDC9 may also possess redox activity. This hypothesis was
confirmed first in the insulin-reduction assay, where recombinant hTXNDC9 displayed a
redox activity similar to that of recombinant PbPhLP1. In addition, hTXNDC9 was
shown to accept electrons from its endogenous thioredoxin, and the kinetic values
between the Plasmodium and human proteins were comparable. These results represent
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an important finding for hTXNDC9, as the possibility of redox activity of the TXNDC9
homolog in C. elegans, C05D11.3, has previously been dismissed due to the lack of a
characteristic CXXC active site motif (Ogawa et al, 2004). Our results indicate the
possibility that all PbPhLP1 homologs may possess redox activity. It may therefore be
necessary for potential functions and mechanisms to be reconsidered in light of these
findings.
In addition, a previous study of thioredoxin domain containing proteins using
computational structure-based approach did not report on any active site motif in
members of the phosducin-like family of proteins (Atkinson and Babbitt, 2009). While
most of the characterized redox active thioredoxins contain a characteristic CXXC active
site motif, it has been shown that a number of thioredoxins or thioredoxin-like proteins
either lack the N-terminal or C-terminal cysteine or do not contain an apparent active site
(Herrero and de la Torre-Ruiz, 2007). These so-called atypical active sites commonly
contain serine or threonine residues in place of one of the cysteines (Atkinson and
Babbitt, 2009). This appears to be the case for PbPhLP1 and hTXNDC9, since threonine
is present in place of the N-terminal cysteine in both proteins.
We are confident that the reduction of redox activity observed when PbPhLP1 is
mutated is due to the absence of the redox active Cys106 rather than a change in the
structure of the protein for the following reasons. Stabilizations of protein structures by
disulfide bridges rarely occurs in cytoplasmic proteins due to the reducing nature of the
cytoplasm (Alberts et al, 2008). Our own observations in Plasmodium parasites
combined with previous reports on PbPhLP1 homologs indicate an intracellular rather
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than extracellular localization of these proteins. Our hypothetical models of PbPhLP1 and
hTXNDC9 also suggest that the conserved redox active cysteine is located on the surface
of these proteins rather than buried within the structure. It therefore seems unlikely that
the mutation of this cysteine to a serine would introduce any sort of significant
conformational change in the protein that may account for the decrease in redox activity.
While the results of my investigations of the cellular expression of PbPhLP1 were
inconclusive, my observations also suggest that there may be epitopes that are conserved
between PbPhLP1 and tubulin. My Western blot analyses show that anti-PbPhLP1
antibodies cross-react with purified tubulin. My IFAs also show that the anti-PbPhLP1
antibodies clearly stain the microtubular network of human cells. In addition, Western
blots showed that anti-beta tubulin antibodies cross-react with recombinant PbPhLP1.
However, the anti-PbPhLP1 antibodies were also able to recognize recombinant
hTXNDC9 on a Western blot, suggesting that at least some of the staining pattern
observable in the IFAs may be due to hTXNDC9. These results do not represent the first
time that a cross-reaction was observed between cytoskeletal elements and antibodies
developed against a member of the phosducin-like family of proteins (Piotrowska and
Adler, 2010). Since PbPhLP1 may interact with tubulin in vivo, a further exploration of a
common epitope between the two proteins is warranted. However, for the purpose of this
project, these results only serve to suggest that the polyclonal PbPhLP1 antibodies are not
useful for studies of PbPhLP1. However, considering the possibility of common epitopes
between PbPhLP1 and tubulin, a logical future step would be the development of a
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monoclonal antibody against PbPhLP1 to advance cellular studies and the investigation
of putative interactions between this protein and the cytoskeletal network.
The reason we pursued a possible interaction between PbPhLP1 and the
cytoskeleton was that other studies also pointed to an interaction between PbPhLP1
homologs and the cytoskeleton. As mentioned, disruption of this protein in both C.
elegans and A. thaliana led to observable defects in the microtubular network of these
organisms (Ogawa et al, 2004; Castellano and Sablowski, 2008). In A. thaliana, PhLP3
was shown to be required for the microtubule-dependent steps of cell division (Castellano
and Sablowski, 2008). It is my hypothesis that the KO of phlp1 in P. berghei may
therefore have been lethal because the integrity of the cytoskeletal network had been
compromised, ultimately leading to cell death. An alternative method to investigate the
cellular function of phlp1 would be overexpression of the gene. This method has been
shown to cause microtubule disassembly and an imbalance of α and β tubulin subunits in
a mammalian system (Hayes et al, 2011).
My hypothesis that PbPhLP1 is involved in maintenance of the cytoskeleton is
based on observations that members of the thioredoxin-like family of proteins can
interact with cytoskeletal components. For example, the tubulin heterodimer contains a
high number of cysteine residues (20 in the mammalian protein) and may therefore be
susceptible to oxidative stress (Lowe et al, 2001; Luduena et al, 1991). Oxidation of key
cysteine residues by reactive oxygen species (ROS) leads to tubulin disulfide formation
and subsequent loss of function due to the inhibition of tubulin polymerization (Landino
et al, 2004). Since ROS are a common occurrence in cells, the microtubules would
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require a maintenance and repair system in cells that reduces these destabilizing disulfide
bridges. One study reports that the thioredoxin system can maintain the stability of
microtubules in vitro by keeping the cysteines present in tubulin in a reduced state.
(Landino et al, 2004). Similar findings were shown for the microtubule-associated
proteins tau and microtubule-associated protein-2 (MAP-2) (Landino et al, 2004).
Peroxynitrite and hydrogen peroxide caused the oxidation in these proteins, leading to a
decreased ability to promote microtubule assembly from tubulin subunits. Treating
oxidized tau and MAP-2 with the thioredoxin system restored their ability to promote
microtubule assembly. These findings show that disulfide bonds present in both tubulin
and microtubule-associated proteins may be reduced by the thioredoxin system.
Therefore these studies suggest that the redox activity that we observed for
PbPhLP1 and hTXNDC9 may be important for some function involving an interaction
with tubulin, a hypothetical interaction supported by previous studies (Blaauw et al,
2003; Ogawa et al, 2004; Castallano and Sablowski, 2008). In addition, one study on
hTXNDC9 suggested that this protein may be involved in the CCT-mediated folding of
tubulin subunits (Stirling et al, 2006). Further experiments are necessary in order to
confirm the findings in this study and also to determine if the activity of this protein plays
any role in this putative function.
While KO experiments in S. cerevisiae and D. discoideum suggested this protein
was not essential for the survival of these organisms (Flanary et al, 2000; Blaauw et al,
2003), we hypothesize that the difference between my KO results and the results from
these experiments are due to a difference in the putative active sites of these proteins. S.
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cerevisiae was notably absent from our phylogenetic tree, suggesting that this protein in
yeast may not be a homolog of PbPhLP1 or hTXNDC9. In addition, a recently
constructed phylogenetic tree rooted on the putative active site of PbPhLP1 placed fungi,
including D. discoideum, in a different clade of the tree entirely. This suggests that
differences in the putative active sites of these proteins may be linked with differences in
their roles in their respective organisms. Therefore, D. discoideum PhLP3 may not be
redox active or have an important function in this organism, while other eukaryotic
homologs that are present in different clades than D. discoideum in this tree may be redox
active and essential for these species. These findings should therefore be taken into
account when studying potential functions of these proteins.
In conclusion, this project identifies PbPhLP1 as a highly conserved novel
thioredoxin domain-containing, phosducin-like protein that is essential for the malaria
parasite P. berghei. PbPhLP1, as well as its human homolog hTXNDC9, was shown to be
redox active as well as able to accept electrons from the thioredoxin system. This project
represents the first biochemical characterization of any phosducin-like protein. The
results presented here provide insights into the functional mechanism of these highly
conserved proteins.
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